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1.1 Neurotransmitter transporters 
 
The neuronal communication in the nervous system relies on the action of 
neurotransmitters at chemical synapses between neurons. An action potential 
promotes the release of the neurotransmitter, increasing its concentration 103–104-fold 
in the synaptic cleft. After being released, neurotransmitters specifically bind to 
postsynaptic receptors and thereby activate them. The neurotransmitter opens ligand-
gated ion channels, resulting in depolarization of the postsynaptic neuron and the 
generation of a postsynaptic receptor potential. This process, depending on the 
receptor type, leads to excitation or inhibition of the postsynaptic neuron. Intercellular 
communication in the central nervous system (CNS) requires the precise control of the 
duration and intensity of the neurotransmitter action. This regulation occurs via the 
inactivation of the transmitter, either by enzymatic degradation or active transport by 
neurotransmitter transporters. At many synapses integral membrane transport proteins 
located on presynaptic, postsynaptic and glial cells clear the transmitter from the 
synaptic cleft, reducing the concentration of transmitter to the basal level, thereby 
readying the synapse for a subsequent cycle of activation (Clements, 1996). The 
superfamily of plasma membrane transporters (Masson et al., 1999) can be classified 
into two distinct families based on their ionic dependency. The first is the 
neurotransmitter sodium symporter family (NSS), which consists of Na+/Cl--
dependent transporters including, for example, transporters for dopamine (DAT), 
serotonin (5-HT, SERT), GABA [GAT(1-3)], norepinephrine (NET), proline (PROT), 
taurine (TaurT), and glycine [GLYT(1a, -b, -c, and -2)]. All NSS proteins share the 
same topology and are 40 % to 60 % homologous to one another. The second family 
of the plasma membrane transporters is the family of sodium/dicarboxylate amino 
acid cation symporters (DAACS), which contains the eukaryotic Na+/K+-dependent 
glutamate transporters (excitatory amino acid transporters 1 to 5, or EAATs) and also 
includes prokaryotic glutamate, dicarboxylate and serine transporters. This study 
focuses on members of this last group, the glutamate transporters. The following 
sections will briefly introduce the relevant glutamate transporters existing in 
eukaryotes and their prokaryotic paralogs. As glutamate is the predominant 
neurotransmitter in many excitatory pathways of the mammalian CNS, understanding 
the mechanisms underlying coupled transport by glutamate transporters has high 
importance and was the target of this work.  
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1.2 L-glutamate as a neurotransmitter 
 
The amino acid L-glutamate (Fig. 1.1), abbreviated as Glu or E, is a non-
essential amino acid in vertebrates. It serves as a component of protein synthesis, 
energy metabolism and as predecessor for glutamine and also functions as the major 
excitatory neurotransmitter in the mammalian CNS (Fonnum, 1984; Cotman et al., 
1987; Robinson et al., 1987; Takeuchi, 1987).  
 
 
 
 
Figure 1.1 Chemical structure of L-glutamate. 
 
Glutamate is ubiquitously distributed in brain tissue, where it is present in high 
concentrations in comparison to other amino acids. Glutamate is involved in most 
processes and aspects of normal brain function, including memory, learning and 
cognition (Fonnum, 1984; Danbolt, 2001). Glutamate also plays major roles in many 
processes during CNS development, including neuronal migration (Rossi et al., 1993; 
Komuro et al., 1993) and GABAergic activity (van den Pol et al., 1998), as well as 
outgrowth of neuronal processes (Pearce et al., 1987). Furthermore, glutamate is 
important for synapse elimination (Rabacchi et al., 1992), and for functional synapse 
induction in the developing nervous system and also for long-term potentiation 
(Durand et al., 1996).  
Brain glutamate is abundant, but mostly intracellular. The concentration 
gradient of glutamate across the plasma membranes has a magnitude of several 
thousand, with the highest concentrations found inside nerve terminals (Danbolt, 
2001). Glutamate is continuously being released from cells and again removed from 
the extracellular fluid. Upon production of the action potential, L-glutamate is 
released from the presynaptic neuron into the synaptic cleft. After its release, the 
concentration of glutamate in the synaptic cleft rises from 1 µM to 1 mM and elicits 
the postsynaptic answer through interaction with glutamate receptors. Synaptic release 
of glutamate may activate several ionotropic and metabotropic receptors to mediate a 
complex array of functions. Glutamate taken up by pre- and postsynaptic cells may be 
used for metabolic purposes such as protein synthesis and energy metabolism; in pre-
synaptic cells it also may be reused as a transmitter (Danbolt, 2001). Glutamate taken 
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up by glial cells can be converted to glutamine in an ATP-dependent process 
(glutamate-glutamine cycle) (Broer et al., 2001). Glutamine is subsequently released 
from the glial cells and taken up by neurons via glutamine transporters. Neurons 
convert glutamine back to glutamate, which is then transported into the synaptic 
vesicles by vesicular glutamate transporters (Broer et al., 2001).  
Glutamate is a neurotoxin. At concentrations between 50 µM and 100 μM 
glutamate causes cell death after 5 minutes. Already after 90 seconds glutamate 
application produces the first morphologic changes in adult neurons (Choi et al., 
1987). It is therefore crucial that the resting extracellular glutamate concentration 
remains low. This is required for a high signal to background ratio in synaptic 
transmission and also for the protection of nerve cells from the toxic effects of 
glutamate. Considering the large amounts of glutamate in the brain and the importance 
of controlling the extracellular glutamate concentrations after its release, the CNS 
needs powerful protective machinery to prevent extracellular glutamate accumulation. 
In contrast to extracellular glutamate, intracellular glutamate is generally considered 
non-toxic (Danbolt, 2001). Finally, to conserve resources it is practical to reuse the 
released glutamate. Glutamate is removed by the neuronal and glial glutamate 
transporters, which Arriza et al. (1994) have termed „Excitatory Amino Acid 
Transporters“ (EAATs). Members of the EAAT family tightly control the glutamate 
concentration in the synaptic cleft (Billups et al., 1996; Kanner, 1996; Danbolt, 2001; 
Amara et al., 2002). EAATs are located in presynaptic, postsynaptic and glial cells 
and they rapidly remove glutamate from the synaptic cleft and the perisynaptic area.  
 
1.2.1 Role of glutamate uptake in disease 
 
Brain tissue needs a very high glutamate uptake activity to protect itself 
against glutamate toxicity because there is no extracellular conversion of glutamate 
(Danbolt, 2001), as there is for example for acetylcholine. Removal of glutamate from 
the synaptic cleft has high importance for two reasons: (1) the neurotoxicity of 
glutamate and (2) the necessity of exact and accurate regulation of signal transduction 
by the inactivation of glutamate (Danbolt, 2001). Rapid clearance of glutamate from 
the synapse by high-affinity sodium-dependent EAATs is required for normal 
excitatory neurotransmission and for the prevention of glutamate-induced 
excitotoxicity (Bergles et al., 1999; Danbolt, 2001). Failure in EAAT function 
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provokes neuro-excitotoxicity by elevation of the extracellular glutamate 
concentration, causing excessive stimulation of the glutamate receptors that, if 
prolonged, will result in processes leading to cell death (Rossi et al., 2000). A link 
between glutamate transporter dysfunction, increased extracellular glutamate level, 
and the onset of excitotoxic neuronal damage has been established in animal models 
(Rothstein et al., 1996) and in some human neurodegenerative diseases such as 
amyotrophic lateral sclerosis (ALS) (Rothstein et al., 1992; Rothstein et al., 1995; 
Howland et al., 2002), Alzheimer’s disease (Scott et al., 1995; Scott et al., 2002), 
apoplexy (Rothman, 1984), epilepsy (Nadler et al., 1978), schizophrenia, and 
depression (Dingledine et al., 1999). For this reason it is of high importance to study 
and understand the mechanisms underlying glutamate uptake by glutamate 
transporters.  
 
1.3 Glutamate transporters 
 
Glutamate transporters belong to the DAACS family (see section 1.1), which 
includes eukaryotic glutamate transporters, eukaryotic neutral amino acid transporters, 
and a large number of bacterial amino acid and dicarboxylic acid transporters 
(Slotboom et al., 1999; Danbolt, 2001; Kanai et al., 2003). Members of this family 
that have been functionally characterized can be classified into three groups based on 
their substrate specificity: (1) C4-dicarboxylate transporters found in prokaryotes, (2) 
glutamate/aspartate transporters found in prokaryotes and eukaryotes and (3) neutral 
amino acid transporters found in prokaryotes and eukaryotes (Slotboom et al., 1999). 
The phylogenetic tree of the DAACS family is presented in Fig. 1.2.  
All glutamate transporters can use L-glutamate, L-aspartate and D-aspartate as 
high-affinity substrates. The bacterial C4-dicarboxylate transporters transport 
succinate, fumarate, and malate, thereby contributing to the citric acid cycle (Finan et 
al., 1981; Finan et al., 1988). This group of transporters shares up to 40 % amino acid 
sequence identity with each other. Alanine, cysteine, serine, and threonine are high 
affinity substrates of the neutral amino acid transporters. Some members of this group 
show lower substrate specificity and also accept glutamine and asparagine with higher 
affinity, and some other amino acids with lower affinity (Arriza et al., 1993; 
Tamarappoo et al. 1996; Utsunomiya-Tate et al., 1996; Kekuda et al., 1996; Kekuda 
et al., 1997).  
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Figure 1.2 Phylogenetic tree of 35 members of the DAACS family (Slotboom et al., 1999). The tree 
is based on the part of the multiple-sequence alignment (Slotboom et al., 1999). No members of the set 
have higher than 70 % amino acid identity to one another. Abbreviated transporter names are shown in 
Table 7.1. 
 
1.3.1 Mammalian glutamate transporters (EAAT family) 
 
Excitatory amino acid transporters (EAATs) remove glutamate from the 
synaptic cleft to ensure low resting glutamate concentrations and to terminate 
glutamatergic synaptic transmission. Five different mammalian high-affinity sodium-
dependent glutamate transporters (EAAT1-5) have been cloned so far. EAAT1, 2 and 
3 were cloned from human motor cortex (Storck et al., 1992; Pines et al., 1992; Kanai 
et al., 1992; Arriza et al., 1994). EAAT4 was cloned from human cerebellum 
(Fairman et al., 1995) and EAAT5 was cloned from human retina (Fairman et al., 
1995; Arriza et al., 1997). Figure 1.3 shows the phylogenetic tree of some members of 
this family. 
Only the human isoforms of the excitatory amino acid transporters are termed 
EAATs, homologues in other species that were in some cases cloned earlier are 
GLAST (Glutamate Aspartate Transporter, rat equivalent of human EAAT1) (Storck 
et al., 1992), GLT1 (Glutamate Transporter 1, rat equivalent of human EAAT2) 
(Pines et al., 1992) and EAAC1 (Excitatory Amino Acid Carrier 1, rabbit equivalent 
of human EAAT3) (Kanai et al., 1992). The five cloned EAAT glutamate transporters 
 
Bacterial dicarboxylate 
transporters  
Bacterial serine 
transporters 
Bacterial glutamate transporters 
Mammalian glutamate 
transporters (EAATs) 
ASC (alanine, serine, cysteine) 
transporters 
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share 50 % to 60 % amino acid sequence identity with each other, and typically have 
30 % to 40 % identity to transporters for neutral amino acids (Arriza et al., 1993), and 
20 % to 30 % identity to proton-dependent bacterial glutamate and dicarboxylate 
transporters (Tolner et al., 1992; Danbolt, 2001). Among mammals, the five cloned 
glutamate transporter subtypes are approximately 90 % identical to their homologues 
in different species (Danbolt, 2001). 
 
Figure 1.3 Phylogenetic tree of some mammalian members of the glutamate transporter family. 
Glial glutamate transporters: hEAAT1 (Arriza et al., 1994; Larsson et al., 1996), rGLAST (Storck et 
al., 1992; Larsson et al., 1996), mEAAT1 (Tanaka, 1993), hEAAT2 (Arriza et al., 1994), mEAAT2 
(Kirschner et al., 1994), rEAAT2 (Pines et al., 1992). Neuronal glutamate transporters: hEAAT4 
(Fairman et al., 1995), mEAAT4 (Maeno-Hikichi et al., 1997), rEAAT4 (Lin et al., 1998), hEAAT5 
(Arriza et al., 1997), hEAAT3 (Arriza et al., 1994), mEAAT3 (Mukainaka et al., 1995), rEAAT3 
(Kanai et al., 1995; Larsson et al., 1996). Abbreviations: human (h), mouse (m), and rat (r) isoforms. 
 
All five EAATs proteins catalyze H+-, Na+- and K+-coupled transport of L-
glutamate and also of L- and D-aspartate. Originally, these transporters were referred 
to as the “sodium-dependent high-affinity transporters” to distinguish them from the 
“low-affinity transporters”. “Low-affinity” uptake has Km values of above 500 μM 
and, in contrast to the “high affinity system”, is sodium independent and sensitive to 
inhibition by D-glutamate and L-homocysteate. This uptake system has been 
rEAAT3
mEAAT3
hEAAT3
rEAAT2
mEAAT2
hEAAT2
hEAAT5
rEAAT4
mEAAT4
hEAAT4
mEAAT1
rGLAST
hEAAT1
    Neuronal 
       Glial 
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Postsynaptic dendritic spine 
Impulse transmission 
Electrical excitation 
 
Presynaptic ending 
suggested to supply brain cells with amino acids for metabolic purposes, but is poorly 
characterized (Danbolt, 2001). 
The neurotransmission of the signal and cell specific expression of the five 
EAATs are schematically demonstrated in simplified view of two excited nerve cells 
(Fig. 1.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Signal transmission between two excited nerve cells by the neurotransmitter glutamate 
and its removal from the synaptic cleft via glutamate transporters (EAATs).  
  
The localization of EAATs is well known. EAAT2 is the main glial glutamate 
transporter and the most abundant isoform in the forebrain (Danbolt et al., 1992; 
Rauen, 2000). EAAT1 is a glial glutamate transporter, expressed in astrocytes and 
Bergmann glia in the cerebellum (Storck et al., 1992; Rothstein et al., 1994). EAAT3 
is homogeneously distributed throughout the CNS. It is the predominant EAAT 
expressed in neurons of various brain areas, particularly in the thalamus, cerebellum, 
hippocampus, olfactory bulb, and striatum (Rothstein et al., 1994; Kanai et al., 1995; 
Berger et al., 1998). EAAT4 is the main cerebellar glutamate transporter, specifically 
in the Purkinje cells (Yamada et al., 1996; Furuta et al., 1997; Dehnes et al., 1998; 
Inage et al., 1998). A study using electron microscopy found the majority of the 
EAAT4 immunoreactivity in the plasma membrane of Purkinje cells and that the 
highest levels are extra-synaptic (Dehnes et al., 1998). Very little is known about 
EAAT5. This isoform seems to be retina-specific (Arriza et al., 1997; Eliasof et al., 
1998a; Eliasof et al., 1998b). It is present in both cone and rod photoreceptors as well 
Glial cell 
EAAT5 
EAAT1 / EAAT2 
EAAT3 / EAAT4 
Glutamate 
 
Glutamate receptor 
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as in amacrine, ganglial (Fyk-Kolodziej et al., 2004), bipolar and Müller cells (Eliasof 
et al., 1998b). 
Glutamate uptake also takes place in peripheral tissues and organs. Most cells 
and tissues have the ability to take up glutamate. Sodium-dependent glutamate uptake 
systems have been identified in fibroblasts from various tissues, in erythrocytes, 
macrophages,  platelets, muscles, prostate, liver, taste buds, mammalian oocytes, the 
intestine, kidney, pancreas, placenta, heart, bone and mammary gland (Danbolt, 
2001).  
 
1.3.2 Bacterial glutamate transporters 
 
Bacterial glutamate transporter proteins are nutritional transporters. Thus, in 
prokaryotes, glutamate transporters carry out the concentrative uptake of metabolites 
across the membrane by the co-transport of protons and/or sodium ions (Slotboom et 
al., 1999). 
Prokaryotic glutamate transporters are only distantly related to eukaryotic 
glutamate transporter isoforms (Fig. 1.2). Bacterial glutamate transporter proteins 
have more than 44 % amino acid homology and transport at least two cations in 
symport with glutamate (Tolner et al., 1992; Tolner et al., 1995a; Tolner et al., 
1995b). In Escherichia coli (E. coli) internalised glutamate is used as a carbon and 
nitrogen source (Halpern et al., 1965). As far as is known, E. coli has three different 
systems to take up glutamate: (1) a sodium-independent protein-dependent glutamate- 
and aspartate transport system, which is inhibited by cysteate (Halpern et al., 1973), 
(2) a sodium-dependent glutamate specific system (ecgltS), inhibited by α-methyl 
hydrate (Miner et al., 1974), and (3) a proton symport system for glutamate and 
aspartate (ecgltP), inhibited by o-hydroxy aspartate and cysteate (Schellenberg et al., 
1977). This study focuses on this last protein, ecgltP from E. coli. 
Bacterial glutamate transporters have aroused a lot of interest because the 
three-dimensional structure of the glutamate transporter GltPh from archaebacterium 
Pyrococcus horikoshii (P. horikoshii) was recently determined (Yernool et al., 2004). 
In addition, because the overexpression of protein in bacteria results in much higher 
yields of protein, in comparison to eukaryotic cell expression systems (Kück, 2005), 
and the experimental success depends on the amount and purity of the produced 
protein, it is technically more feasible to study prokaryotic paralogs. 
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1.3.3 Stoichiometry 
 
Glutamate transporters belong to the class of secondary active transporters that 
can use the potential energy of ion gradients to transport specific substrates against 
their concentration gradients. Glutamate transporters exhibit two fundamentally 
different transport mechanisms: the first is the coupled co-transport of substrate 
(glutamate or aspartate), with sodium, protons and potassium (Levy et al., 1998; 
Zerangue et al., 1996) and the second is a thermodynamically uncoupled, channel-like 
anion transport (anion channel function) (Fairman et al., 1995; Wadiche et al., 1995; 
Larsson et al., 1996; Billups et al., 1996; Melzer et al., 2003). The exact molecular 
basis of these two diverse functions is not yet understood. The ion gradients of sodium 
and potassium ions and also protons deliver the driving force for glutamate uptake 
(Zerangue et al., 1996).  
EAAT2 and EAAT3 have been shown to exhibit the following stoichiometry: 
the co-tansport of one glutamate molecule, three sodium ions and one proton into the 
cell is coupled to the counter-transport of one potassium ion out of the cell (Kanner et 
al., 1978; Stallcup et al., 1979; Schwartz et al., 1990; Szatkowski et al., 1990; 
Barbour et al., 1991; Erecinska et al., 1983; Zerangue et al., 1996), see Fig. 1.5. It 
cannot be taken for granted that EAAT1, EAAT4, and EAAT5 share the same 
stoichiometry. 
 
 
 
Figure 1.5 Stoichiometry of glutamate transporters. Coupled transport stoichiometry of mammalian 
glutamate transporters. One excitatory amino acid (EAA) molecule, three sodium ions (Na+) and one 
proton (H+) are co-transported into the cell and one potassium ion (K+) is counter-transported outside.  
 
Various EAATs paralogs have been identified in prokaryotes and shown to 
exhibit a variety of transport stoichiometries. Although these transporters have similar 
predicted structures, they exhibit distinct functional properties such as variations on a 
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common transport mechanism (Arriza et al., 1994; Melzer et al., 2003; Mim et al., 
2005). Whereas EAATs transport three sodium ions, one proton, and one glutamate 
molecule in counter-transport with one potassium ion, there are bacterial paralogs that 
only transport substrate (glutamate, aspartate) stoichiometrically coupled to protons, 
or to sodium. The glutamate transporters from Escherichia coli and from Bacillus 
subtilis use protons to drive glutamate uptake, and the glutamate transporter from 
Escherichia coli only depends on a proton gradient. The glutamate transporter from 
Pyrococcus horikoshii catalyzes aspartate transport solely coupled to sodium 
(Boudker et al., 2007; Ryan et al., 2009). A sodium / proton / L-glutamate symport 
has also been found for the glutamate transporters from Bacillus stearothermophilus 
and Bacillus caldotenax (Heyne et al., 1991). However, these transporters lost their 
coupling sodium selectivity when they were expressed in E. coli (Tolner et al., 1995a; 
Tolner et al., 1995b). 
Interest in bacterial glutamate transporters is high because there are indications 
that, by comparison, glutamate transport in eukaryotes is more complex and bacterial 
glutamate transporters exhibit less complicated transport processes, enabling more 
convenient analysis of the bacterial systems. In this work ecgltP, the glutamate 
transporter from E. coli, was used as a model protein to study the mechanisms 
underlying coupled glutamate transport. 
 
1.3.4 Structure 
 
Although they possess different functions, bacterial and mammalian glutamate 
transporters share strong homology to one another. Prokaryotic and eukaryotic 
glutamate and neutral amino acid transporters possess significant amino acid sequence 
homology throughout the entire primary structure, as revealed by multiple sequence 
alignments (Slotboom et al., 1999).  
Glutamate transporters are integral membrane proteins. Members of the 
glutamate transporter family share (1) similar transmembrane topology (Fig. 1.7) and 
(2) trimeric oligomerisation state (Gendreau et al., 2004; Yernool et al., 2004). ecgltP 
consists of 437 amino acids and a molecular mass of monomer is 47.2 kDa.  
ecgltP has a typical amino acid composition for membrane proteins: 66.3 % of 
amino acids are non-polar and 32.7 % are polar, 6.9 % are basic and 6.4 % acidic. 
ecgltP shares 48 % sequence homology and 22 % identity with the human EAAT2 
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isoform. GltPh shares 37 % amino acid identity with human EAAT2. GltPh and ecgltP 
are 33 % identical and 55 % homologous in their primary sequences (Fig. 1.6, Fig. 1.7 
B), (Table 7.2). A stretch of about 150 residues in the C-terminal half is particularly 
well conserved (Slotboom et al., 1999). This half of the protein contains several 
sequence motifs involved in recognition and/or translocation of glutamate and co-
transported cations (Slotboom et al., 2001b).  
 
 
 
 
 
 
Figure 1.6 Phylogenetic relationship of three distantly related glutamate transporters GltPh, 
ecgltP, and hEAAT2. The phylogram is based on a multiple amino acid sequence alignment of 
respective sequences GltPh (Accession no. AB009510), ecgltP (Accession no. P21345), hEAAT2 
(Accession no. P43004) (ClustalW, Chenna et al., 2003). Abbreviations: glutamate transporter from 
archaebacteria P. horikoshii (GltPh), bacterial glutamate transporter from E.  coli (ecgltP), and human 
isoform of excitatory amino acid transporters (hEAAT2). 
 
According to the crystal structure of the bacterial glutamate transporter GltPh 
from Pyrococcus horikoshii, the glutamate transporter is a bowl-shaped trimer (Fig. 
1.8) with a solvent-filled extracellular basin extending halfway across the membrane 
bilayer. At the bottom of the basin are three independent binding sites, each cradled 
by two helical hairpins, facing opposite sides of the membrane. Transport of 
glutamate is thought to be mediated by movements of the hairpins that allow 
alternating access to either side of the membrane (Yernool et al., 2004). 
GltPh is a homotrimer, each subunit of which consists of eight transmembrane 
helices. Each protomer (Fig. 1.9) contains eight transmembrane segments, two re-
entrant helical hairpins, and independent substrate translocation pathways. The first 
six transmembrane segments form a distorted “amino-terminal cylinder” and provide 
all interprotomer contacts, whereas transmembrane segments TM7 and TM8, together 
with hairpins HP1 and HP2, assemble to form a highly conserved core within the 
amino-terminal cylinder (Boudker et al., 2007). 
 
 
 
 
 
 1. Introduction 13 
 
 
 
Figure 1.7 Sequence identities of three distantly related glutamate transporters GltPh, ecgltP, and 
hEAAT2. (A) Schematic draw of transmembrane topology of glutamate transporters (modified from 
Yernool et al., 2004). (B) Multiple amino acid sequence alignment of respective sequences (ClustalW, 
Chenna et al., 2003). The rectangles above the sequences show the distributing of secondary structure 
elements based on results of the crystal structure of GltPh (Yernool et al., 2004). Glutamate binding 
domains are marked in black, highlighted with a brown rectangle. Abbreviations: * = identical amino 
acids, : conserved exchange, . semi-conserved exchange (ordered according to classification into basic, 
acidic, small and hydrophobic amino acids).  
B
A
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Figure 1.8 Crystal structure of a bacterial glutamate transporter GltPh from Pyrococcus 
horikoshii (Yernool et al., 2004). (A) Ribbon representation of the trimeric protein, in which the 
protomers are shown in red, blue and green, shown from the extracellular side of the plasma membrane. 
(B) View of the trimer parallel to the membrane. 
 
 
 
 
 
Figure 1.9 Protomer. Ribbon representation of the protomer viewed in the plane of the plasma 
membrane in which the transmembrane helices (1-8) and hairpins (HP1, HP2) are labelled and are 
shown in different colours (Yernool et al., 2004). 
 
 
 
BA
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The carboxy-terminal half of eukaryotic and prokaryotic transporters 
encompasses residues that are crucial for substrate binding, substrate transport and ion 
coupling (Kanner et al., 2002; Yernool et al., 2004 ; Boudker et al. 2007), whereas 
residues in the amino-terminal part are implicated in the thermodynamically 
uncoupled chloride flux (Ryan et al., 2004). 
Particularly, the arginine residue at position 447 was shown to play a role in 
determining substrate selectivity in EAAT3 (Bendahan et al., 2000). The glutamate 
residue at position 373 was proposed to be the proton acceptor in EAAT3 (Grewer et 
al., 2003). The same glutamate residue in GLT-1, the rat homolog of EAAT2 (E404), 
was proposed to bind K+ (Kavanaugh et al., 1997). Aspartate residues at position 367 
of EAAT3 (Tao et al., 2006; Tao et al., 2007) and 405 of GltPh (Boudker et al., 2007), 
were shown to be crucial for sodium binding.  
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1.4 Aim of the thesis 
 
This study focuses on the molecular, biochemical and functional 
characterization of a model transport protein, the bacterial glutamate transporter from 
Escherichia coli – ecgltP – using the methods of mutagenesis, protein purification 
with subsequent reconstitution into artificial lipid vesicles, and quantification of 
radiotracer substrate fluxes into proteoliposomes. The possibility of studying a 
purified prokaryotic glutamate transporter protein using functional tests without 
contaminations with other cellular compartments gives, in combination with the 
available structural information, promising preconditions for the determination of 
transport mechanisms of glutamate transporters. 
This project aims to characterize the functional properties of glutamate 
transporters in order to gain insights into the molecular mechanisms underlying 
coupled transport. To learn more about the structural basis of the transport properties 
of this prokaryotic glutamate transporter, the wild type ecgltP protein was 
characterized and compared with transporter carrying mutation, potentially affecting 
sodium binding (Fig. 1.10). N401D ecgltP contains an aspartate residue in TM8 at a 
position homologous to D405 of GltPh (Boudker et al., 2007), which was shown to be 
crucial for sodium binding.  
    
 
 
Figure 1.10 Localization of the N401D mutation. Schematic representation of ecgltP transmembrane 
topology showing the localization of mutated residue.  
 
 
 
 
N401D 
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2.1 Chemicals, materials and equipment  
 
2.1.1 Materials and equipment 
 
Equipment and materials were obtained from the following companies: Avestin 
Inc. (Ottawa, Canada), BD Microlance (USA), Beckman Coulter, Inc. (USA), Bio-Rad 
Laboratories GmbH (München, Germany), Biometra (Göttingen, Germany), Branson 
Ultrasonics Corp. (Danbury, USA), Corning (New York, USA), Eppendorf (Hamburg, 
Germany), GE Healthcare Bio-Sciences, formerly Amersham Biosciences (United 
Kingdom), Greiner Bio-One GmbH (Frickenhausen, Germany), G. Kisker GbR 
(Steinfurt, Germany), Hamilton Company (Nevada, USA), Heraeus (Newport Pagnell, 
United Kingdom), IBA (Göttingen, Germany), Ibidi GmbH (München, Germany), 
Infors HT AG (Bottmingen, Switzerland), Kimberley-Clarke (Roswell, USA), KNF 
Neuberger, Inc. (New Jersey, USA), Millipore Corporation (Billerica, USA), MJ 
Research, Inc. (Waltham, USA), PEQLAB Biotechnologie GMBH (Erlangen, 
Germany), PerkinElmer Life and Analytical Sciences (Rodgau, Germany), PTI (NJ, 
USA), QIAGEN GmbH (Hilden, Germany), Roth (Karlsruhe, Germany), Sartorius 
Biolab Products (Göttingen, Germany), Sarstedt (Nümbrecht, Germany), Schott 
Glaswerke AG (Mainz, Germany), Systat Software, Inc. (Point Richmond, VA, USA), 
Systec GmbH Labor-Systemtechnik (Wettenberg, Germany), VACUUBRAND GmbH 
(Wertheim, Germany), Whatman Laboratory Products, Inc. (Clifton, USA).  
 
2.1.2 Chemicals 
 
All chemicals and solutions had at least a purity grade of p.A. and were obtained 
from AppliChem GmbH (Darmstadt, Germany), ACROS ORGANICS (USA), Avanti 
Polar Lipids (Alabaster, AL, USA), JT Baker Chemical Co., (Phillipsburg, USA), 
Becton, Dickinson and Company (USA/France), Bio-Rad Laboratories GmbH 
(München, Germany), Calbiochem (Bad Soden, Germany), Carl Roth GmbH 
(Karlsruhe, Germany), Decon Laboratories Limited (East Sussex, United Kingdom), 
Fisher Scientific GmbH (Schwerte, Germany), Fluka (Neu-Ulm, Germany), GLYCON 
Biochemicals (Luckenwalde, Germany), Hartmann Analytic GmbH (Braunschweig, 
Germany), KMF Laborchemie Handels GmbH (Lohmar, Germany), Linde (Hannover, 
Germany), Merck KGaA (Darmstadt, Germany), MP Biomedicals, Inc. (Solon, USA), 
New England Biolabs GmbH (Frankfurt, Germany), PerkinElmer Life and Analytical 
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Sciences (Rodgau, Germany), Pierce (Rockford, USA), Serva GmbH (Heidelberg, 
Germany), Sigma-Aldrich (Hamburg, Germany), Stratagene (La Jolla, CA, USA), or 
USB Corporation (USA). Deionised water was prepared at 18.2 MΩ in a Milli Q plus 
system from Millipore (USA). For protein biochemical parts of the work, deionised and 
autoclaved water was also used.  
 
2.2 Molecular biology 
 
2.2.1 Sequence alignments 
 
Sequence alignments were made with use of Vector NTI Advance 10 software 
from Invitrogen (Invitrogen Corporation, CA, USA).  
 
2.2.2 Plasmids 
 
For ecgltP expression the vector pASK-IBA5 from IBA (IBA GmbH, Göttingen, 
Germany) was used. The cDNA encoding ecgltP was subcloned into the pASK IBA5 
vector, which adds an amino-terminal Strep-tag (MASWSHPQFEK). This allows a 
 
single step protein purification to 
purify the strep-ecgltP protein 
using Strep-Tactin® affinity 
chromatography (IBA). pASK 
IBA5 carries an ampicillin 
resistance cassette. The protein 
expression is under the control of 
Tet-promotors/operators, and can 
be induced by anhydrotetracycline 
hydrochloride. 
2.2.3 Mutagenesis 
 
2.2.3.1 Primers and resulting constructs 
 
Table 7.5 shows the primers used for mutagenesis. Each primer was checked in 
Vector NTI Advance 10 (Invitrogen) for the presence of a low amount of predicted 
loops, one or more cytosine or guanine at both termini, a length of 25 to 45 bases, a 
 2. Materials and methods 20 
melting temperature of ≥78 °C, the mutation being in the middle of the primer and no or 
small negative dG (Gibb’s free energy). A low dG value is associated with energetically 
stable interactions between palindromic sequences within primers and should therefore 
be avoided. 
Constructs were made by polymerase chain reaction (PCR) using pASK-IBA5 
ecgltP as the template (2.2.3.2). The desired mutation was introduced by cleavage of the 
PCR product and the DNA fragment was then ligated into the previously mentioned 
vector. Mutation N401D ecgltP was made with the Quikchange method (2.2.3.3) on 
pASK-IBA5 ecgltP with the indicated primers. The sequencing primers were from 
MWG Biotech AG and the Quikchange primers from Sigma Aldrich. All DNA 
constructs were sequenced.  
 
2.2.3.2 Polymerase Chain Reaction 
 
The PCR is a technique based on the work of Mullis (Mullis et al., 1990). Using 
PCR to generate multiple copies of a particular DNA sequence allows the amplification 
and qualitative analysis of DNA fragments. For analytical amplification and 
mutagenesis PCR the Taq-Polymerase (NEB, 5 U/mL) was used. 10-100 ng DNA-
template were mixed with 10 µM of each primer, 200 µM dNTPs and 0.05 U/µL Taq-
Polymerase in 1x PCR buffer. The reaction mixture was incubated in a thermocycler 
where, after denaturation at 94-96 °C for 1 minute, 35 cycles were performed.  
 
Denaturation  1 min   94 °C   
Annealing             1 min  40-72 °C (Tm-10 °C)  
Synthesis  3 min  72 °C 
 
Final synthesis took place at 72 °C for 10 min. The PCR product was purified 
using a QIAquick PCR Purification Kit or was electrophoresed on a 1 % agarose gel 
and then extracted from the gel using the QIAquick Gel Extraction Kit, to remove 
primers, nucleotides, salts and the DNA polymerase. 
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2.2.3.3 Quikchange method 
 
Site-directed Quikchange mutagenesis was performed using a reaction mixture 
containing 50 ng of template DNA, 125 ng sense primer, 125 ng antisense primer, 2 % 
(v/v) 10 mM dNTP mixture (Eppendorf or Qiagen), and 10 % (v/v) 10x reaction buffer 
(Stratagene). The reaction was filled to a volume of 49 µl with HPLC quality water 
before 1 µl of Pfu Turbo DNA polymerase (2.5 U/µl, Stratagene) was added. The 
reaction was performed in a thermocycler, with a starting denaturation for 2 minutes at 
95 °C followed by nineteen cycles.  
 
Denaturating   45 sec  95 °C 
   Annealing  1 min  55 °C 
 Synthesis  1 min/kbp 68 °C 
 
After these cycles the temperature was kept at 68 °C for 10 minutes more to 
allow the completion of the synthesis. The sample was then placed on ice for 2 minutes 
to cool the tube. 10 Units of DpnI (Fermentas or New England Biolabs) were added, 
which resulted in the selective digestion of the template DNA, leaving the mutated 
product intact, as DpnI only digests methylated DNA. Bacterial DNA is methylated, 
however the PCR synthesized DNA is not, as the appropriate enzymes are not present. 
The sample was incubated at 37 °C for 1 hour. Competent bacteria were transformed so 
that the target plasmid could be multiplied. 
 
 
Figure 2.1 Scheme of the Quikchange reaction. 
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2.2.4 Transformation 
 
Transformation of competent BL21 (DE3) and DH5α E. coli cells was 
performed according to the method of Hanahan (Hanahan, 1983), with some 
modifications.  
5 - 10 µl of ligation mixture, respectively 10 to 50 ng DNA purified plasmid 
DNA was added to 40 µl of competent Escherichia coli bacteria. After thawing the 
bacteria, the DNA was added and the mixture was incubated on ice for 20 minutes. The 
tube was transferred to a heat block for 60 seconds at 42 °C and then placed on ice for 2 
minutes. After the addition of 300 µl of LB medium, the bacteria were incubated at 
37°C for 1 hour, shaking at 220 rpm. The bacteria were spun down for 0.5 minutes at 
6,000 rpm, in a table centrifuge. The pellet was resuspended in a small part of the 
supernatant which was than transferred to an agar plate with the appropriate antibiotics 
(typically ampicillin, 0.05 mg/ml) to select for the desired plasmid. The plates were 
inverted to avoid the accumulation of condensed water on the colonies, and incubated 
overnight at 37 °C. For each transformation ligation mixture, a vector alone, a positive 
(50 ng of a high copy plasmid with the same antibiotics resistance) and negative 
(autoclaved deionised water or nothing instead of DNA) controls were used.  
 
2.2.5 Plasmid recovery / purification / storage 
 
Small amounts of DNA were recovered from 6 to 8 ml overnight cultures, grown 
at 37 °C and shaken at 220 rpm, in LB medium with the appropriate antibiotics. 
According to the  protocols of the Qiaprep 8 Miniprep Kit, or Qiaprep Spin Miniprep 
Kit with the use a vacuum pump or table centrifuge as applicable, the plasmids were 
isolated. Larger quantities of DNA were recovered/purified with the Qiagen HiSpeed 
Plasmid Maxi Kit. As preparation, 2 ml of LB medium with the appropriate antibiotics 
were inoculated with transformed E. coli as preculture, which grew at 37 °C for 8 hours. 
The preculture was given into 200 ml LB medium with the appropriate antibiotics. This 
culture was incubated overnight at 37 °C, shaking at 220 rpm . All steps were followed 
as recommended by the manufacturer. For storage, 1 ml of the grown culture was taken. 
The same volume of 50 % glycerol was added before the mix was flash frozen in liquid 
nitrogen. Afterwards these glycerol stocks were kept at –80 °C until used. 
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2.2.6 DNA concentration measurement 
 
DNA concentrations were measured after dilution 1:100 in autoclaved deionised 
water. The optical density (OD) was measured at 260 nm and 320 nm (baseline) in a 
spectrophotometer that automatically calculates the DNA concentration, or the DNA 
concentration was calculated manually. An OD260 of 1 represents 50 µg/µl of DNA. The 
following formula was used for the manual calculation:  
 
c(dsDNA)=ΔA(260 nm-320 nm) · 50 µg/ml. 
 
2.2.7 Agarose gel electrophoresis 
 
Agarose was dissolved in 1x TAE buffer (50x consists of 2 M Tris Base, 5.95 % 
(v/v) of 96 % Acetic acid, 10 % (v/v) 0.5 M EDTA, pH 8.0 or 3.72 % (w/v) Na2EDTA · 
2 H2O), at a concentration dependent on the size of the DNA fragments to be analysed. 
The agarose concentrations used were 1 % (w/v) for fragments smaller than 1000 
basepairs (bp) and 2 % (w/v) for fragments bigger than 1000 bp. Ethidium bromide was 
dissolved in the agarose gels at 0.002 % (v/v) at approximately 60°C. Ethidium bromide 
is an intercalating agent that fluoresces when exposed to UV-light, allowing the 
visualisation of DNA. The lambda DNA/EcoRI+HindIII marker or the GeneRuler DNA 
Ladder Mix was also loaded on the gel to provide a guide to the sizes of the DNA 
fragments. Samples were dissolved in 6x loading buffer (0.25 % bromophenol blue, 
0.25 % xylene cyanol FF, 30-40 % glycerol). Gels were run at 100 V for 1-2 hours, 
DNA-visualisation via a Gel Doc™XR documentation system took place and bands 
were then quantified using the Quantify One program (BioRad) under UV light (with a 
wavelength of 302 nm). Plasmid DNA was isolated from preparative agarose gels using 
the QIAquick Gel Extraction Kit from Qiagen according to the manufacturer’s 
instructions. 
  
2.2.8 DNA Restriction Enzymes 
 
For fragments up to 3000 bp in length, 5 µg and for bigger fragments 3 µg of 
DNA was used. The appropriate amount of DNA was used together with 10 % (v/v) 10x 
enzyme buffer, 1 % (v/v) BSA or SAM if required, the reaction was filled to a volume 
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of 48.5 µl with autoclaved deionised H2O and 1.5 µl of enzyme (New England Biolabs) 
was used. For a double digest with compatible buffers the reaction was filled to 47 µl 
and 1.5 µl of each of the two enzymes were added. When the buffers of the different 
enzymes were not compatible, but differed only in salt concentration, one digest was 
performed for 2 hours after which NaCl and the second enzyme could be added. If there 
were other differences between the two buffers to be used, the digested DNA was PCR 
purified using the Qiaquick PCR Purification Kit or electrophoresed on an agarose gel 
and then extracted from the gel. After these purification steps the DNA was then 
digested with the second enzyme in the appropriate buffer. Test restrictions were 
performed in a total reaction volume of 20 µl, of which 10 % (v/v) was DNA and 5 % 
(v/v) was enzyme. Restriction enzymes were applied in concentrations of from 2 to 10U 
per reaction mix. In preparative reactions from 500 ng to 2 µg DNA was used, and for 
analytical reactions 2-5 µl of miniprep-DNA was used. 
 
2.2.9 Gel extraction 
 
DNA was extracted from agarose gels by a QIAquick Gel Extraction Kit 
according to the manufacturer’s instructions. Alternatively, DNA fragments larger than 
1000 bp were purified with glass milk. The DNA fragment was cut out of the agarose 
gel and weighed. For the glass milk purification the gel was dissolved in 3 volumes of 
filtered sodium iodide solution (6 M NaI, 10 mM Na2SO3, and 20 mM Tris HCl) at 
65°C for at least 5 minutes. The mixture was cooled and then mixed with 10 µl vortexed 
glass milk. The mixture was vortexed several times during 10 minutes of incubation at 
room temperature. Centrifugation at 5,900 g for 10 seconds in a table centrifuge pelleted 
the glassmilk. The pellet was washed with 600 µl NEET wash solution (100 mM NaCl, 
1 mM EDTA, 50 % ethanol, 10 mM Tris HCl, pH 7.5), by vortexing and centrifugation. 
The pellet was washed again with 400 µl NEET wash solution and after removal of the 
supernatant it was additionally centrifuged at 16,100 g. The supernatant was completely 
removed and the glass milk was dried for 10 minutes of centrifugation at 30 °C under 
vacuum in a concentrator (vacuum concentrator 5301 from Eppendorf). The DNA was 
eluted from the glass milk by addition of 30 µl elution buffer from Qiagen and 
incubation for 10 minutes at 65 °C. Centrifugation for 30 seconds at 16,100 g was 
needed to obtain the supernatant. The centrifugation step was repeated to ensure that 
there was no glassmilk left in the DNA fraction.  
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2.2.9.1 Glass milk preparation 
 
50 g of silica was stirred for 1 hour in 200-300 ml of deionised water. After 2 
min without stirring the supernatant was transferred to a beaker and left to stand for 
another minute. The supernatant was discarded and the pellet was centrifuged for 5 
minutes at 1,200 g. The pellet was resuspended in 100 ml 50 % HNO3 and was boiled 
for 1 hour under a hood. After cooling down and centrifugation as before, the silica was 
washed 4 to 6 times with deionised water until the pH was 7.0. The pellet was 
resuspended in an equal volume of deionised water to form a 50 % suspension and was 
frozen at –20 °C in 0.5 ml aliquots. 
 
2.2.10 Ligation 
 
Restriction fragments were separated on a 1 % agarose gel and were visualised 
with the Gel-Documentation system, using the Quantify One program to quantify the 
bands. Ligations were composed of a ratio of 1:3 of the biggest plasmid fragment to the 
inserted fragments, 2 µl T4 DNA ligase buffer, autoclaved deionised H2O to a final 
volume of 19 µl and 1 µl T4 DNA ligase (Fermentas). Ligation took place for 2 hours at 
room temperature or 24 hours at 4 °C. After the ligation reaction was complete the 
bacteria were transformed with the reaction mixture. 
 
2.2.11 DNA sequencing 
 
250 ng of DNA, dissolved in HPLC quality water, was used. To the DNA 
10pmol of sense or antisense primer was added, 2 to 4 µl premix (Big Dye Terminator 
v1.1 Cycle Sequencing Kit from Applied Biosystems) and HPLC quality water to a total 
reaction volume of 10 µl. The sequencing PCR took place in a thermocycler with a 
heated lid for 25 cycles.   
  
Denaturation  30 sec  96 °C 
 Annealing  20 sec  45-52 °C (Tm 5 to 10) 
 Synthesis  4 min  60 °C 
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DNA was purified with a DyeEx 2.0 Spin Kit from Qiagen or by ethanol 
precipitation.  DNA was placed at 90 °C for 2 minutes for denaturing and then was 
incubated for 5 minutes on ice after which the reaction was transferred to a PCR 
sequencing facility (Department of Microbiology of the Hannover Medical School) 
where DNA sequence was analysed using the Genetic Analyser 3130 XL system from 
Applied Biosystems.  
 
2.2.11.1 Ethanol precipitation of sequenced DNA 
 
Sequencing mixture x µl was placed in a 0.5 ml tube and was subsequently 
mixed with a mixture of 90 µl HPLC quality water and 0.1 · x µl 3 M sodium acetate 
pH 5.2 and then with 2.5 · x µl 100 % ethanol (stored at –20 °C), and incubated for 10 
minutes at –20 °C. The mixture was then centrifuged for 20 minutes at 14,000 g after 
which the ethanol was removed. The pellet was washed with 250 µl 70 % ethanol and 
centrifuged for 7 minutes at 16,100 g. The supernatant was removed and the pellet was 
dried for 5 minutes at 30 °C under vacuum. The pellet was dissolved in 2.5 · x µl of 
HPLC quality water. 
 
2.2.12 LB medium, agar plates and antibiotics 
 
LB medium was made by dissolving 22.5 g Difco™ LB Broth, Miller (Luria-
Bertani) in deionised water to a final volume of 900 ml. After dissolving, the solution 
was autoclaved immediately.  For agar plates 22.5 g Difco™ LB Broth, Miller (Luria-
Bertani) and 18 g of Bacto™ Agar were dissolved to a total volume of 900 ml in 
deionised water, stirred and autoclaved. After cooling down to 50 °C the appropriate 
antibiotic was added to the flask to give a final 1x solution. Plates were poured under a 
clean bench and stored dry at 4 °C. In most cases, ampicillin was added. The ampicillin 
stock solution was prepared by dissolving ampicillin powder in autoclaved deionised 
water. A 1000x ampicillin stock solution contained 100 mg ml-1 (150 µg/ml), and was 
aliquoted. Aliquots were stored at –20 °C.  
 
2.2.13 Competent bacteria 
 
For the production of the chemically competent E. coli bacteria, E. coli BL21 
(DE3) or E. coli DH5α bacteria were added to 5 ml of LB medium and incubated 
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overnight at 37 °C, shaking at 250 rpm. 0.4 ml of this culture was diluted in 40 ml LB 
media and this culture of E. coli was grown to its exponential phase at an OD600 of 0.3-
0.5. Bacteria were harvested at 4 °C, 3,000 g for 10 min and were kept on ice from then 
on. The pellet was resuspended in 30 ml TFB I (100 mM RbCl, 50 mM MnCl2 · 2 H2O, 
30 mM potassium acetate, 10 mM CaCl2 · 2 H2O, 15 % (v/v) glycerol, pH 5.8) and was 
incubated for 20 to 90 min on ice. Bacteria were harvested again at 3,000 g at 4 °C for 
10 minutes and were resuspended in 3 ml TFB II (10 mM MOPS, 10 mM RbCl, 75 mM 
CaCl2 · 2 H2O, 15 % (v/v) glycerol, pH 8.0). These competent bacteria were aliquoted, 
immidiatelly frozen in liquid nitrogen and stored at –80°C. 
 
 
2.3 Protein biochemistry 
 
The protocol for the purification of ecgltP is based on the purification protocol 
for ClC channels (Maduke et al., 1999) and has been optimized in our laboratory.  
 
2.3.1 Expression of ecgltP 
 
As a pre-culture for induction, 70 ml LB media in a 250 ml flask was inoculated 
with E. coli BL21 (DE3) or DH5α bacteria cells containing the pASK IBA5-ecgltP 
plasmid, from a glycerol stock. Two flasks of medium were always inoculated to 
produce a sufficient volume of the culture to express the protein on the following day. 
70 µl of 100 mg/ml ampicillin stock in H2O was added to each flask. The following 
incubation was performed overnight at 37 °C, shaking at 250 rpm. 
The pre-culture was diluted 1:50 and grown in 450 ml LB media at 37 °C, 
shaking at 250 rpm until an OD600 of 0.6-0.7, was reached. After this protein expression 
was induced with 200 μg/l anhydrotetracycline hydrochloride (AHT) for the next three 
hours at 37 °C, and the bacteria were then harvested by centrifugation at 5,000 g at 4°C. 
At appropriate stages, before and after induction samples for SDS-PAGE 
(sodiumdodecylsulfat polyacrylamide gel electrophoresis) analysis were taken (see 3.1). 
Bacteria pellets were immediately flash frozen in liquid nitrogen and stored at –80 °C 
until used.  
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2.3.2 Bacteria lysis and membrane pellet preparation 
 
The bacteria pellet (corresponding to 450 ml culture) was thawed on ice for 5-10 
min and resuspended immediately in 40 ml pre-chilled buffer W (100 mM Tris-HCl, 
150 mM NaCl, 1 mM EDTA, pH 8.0). Protease inhibitors were added before before 
bacteria lysis by sonication: 1 µg/ml pepstatin, 10 mM β-mercaptoethanol, 1 µg/ml 
leupeptin, 1 mM PMSF. Sonication was performed on ice for 6 × 20 sec at 40 % power 
using an ultrasound sonifier 450 (Branson Ultrasonics Corp.), while the metal beaker 
was rotated, with a 20 sec pause in between the pulses. The next centrifugation step was 
done immediately at 4 °C in pre-chilled flasks at 12,000 g-15,000 g for 20 min. The 
supernatant was saved and transferred to pre-chilled ultracentrifuge tubes and 
ultracentrifuged for 60 min at 110,000 g at 4 °C to separate the membrane fraction. 
Each pellet was resuspend in 4 ml buffer W supplemented with 250mM sucrose and 
diluted to OD280 = 20. At appropriate stages samples for SDS-PAGE analysis were 
taken (see 3.1). The membrane fraction pellets were aliquoted and immediately flash 
frozen in liquid nitrogen and stored at –80 °C until used.  
 
2.3.3 Solubilization of ecgltP from the membrane pellet  
 
The frozen membrane pellet was thawed on ice. After solubilization of the 
membrane fraction with 15 mM n-Dodecyl-β-maltoside (DDM) for two hours, stirring 
at 4 °C, the solubilization mix was ultracentrifuged for 60 min at 110,000 g at 4 °C. The 
supernatant, containing soluble strep-ecgltP, was retained for further use. To asses 
solubilisation the pellet was resuspend in urea buffer (100 mM NaH2PO4, 10 mM Tris-
HCl, 8 mM urea, pH 8.0) to the original volume, a sample for the SDS-PAGE was taken 
(see 3.1) and the rest was discarded. 
 
2.3.4 Purification of ecgltP by affinity chromatography 
 
ecgltP was purified in one step by affinity chromatography using a Strep-
Tactin® Superflow® High Pressure column and the ÄKTAprime™plus system (from GE 
Healthcare Bio-Sciences) according to the manufacturer’s instruction manual. All 
reagents, solutions, columns and beakers were pre-cooled to the running temperature (4-
6 °C) in chromatography cabinet. The column was stored in buffer R (1 mM HABA in 
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buffer W), giving a red color to the resin. The column was washed twice with 5x 
column volume (CV) of buffer W. Equilibration of the column was performed with 4x 
CV with buffer W supplemented with 1 mM DDM. The supernatant containing the 
solubilized ecgltP protein was diluted 3 to 5 times in buffer W without DDM, to a final 
DDM concentration 3-5 mM.  
After this the protein sample was 
applied to the column. The column was 
washed with 5x CV of 1 mM DDM in 
buffer W until the baseline absorbance 
measured by the UV detector at 280 nm  
was reached, to ensure that all unbound 
proteins were removed. The buffer was 
then changed to the elution buffer E (2.5mM desthiobiotin in buffer W containing 1 mM 
DDM) for the following elution. The eluted protein was collected using the fraction 
collector, with a fraction volume equal to half of the CV. Protein was typically eluted in 
the 4th to 8th fractions. At appropriate stages, a sample for SDS-PAGE analysis was 
taken (see Fig. 3.1).  
 
2.3.5 Size-exclusion chromatography 
 
Purified ecgltP subjected to size-exculsion chromatography (SEC), also called 
gel-filtration or gel-permeation chromatography (GPC). SEC separates molecules of 
different sizes using porous matrix. It is generally used to separate biological molecules, 
and to determine molecular weights and molecular weight distributions of polymers, 
especially for proteins. Molecules larger than the larger pore size of the matrix can not 
enter the pores and elute in the void volume (Vo). Molecules that can enter the pores 
will have an average residence time that depends on the molecule’s size and shape. 
Different molecules therefore have different total transit times through the column. 
Molecules that are smaller than the pore size can enter all pores, and have the longest 
residence time on the column and elute later. The ecgltP sample was loaded to the 
Superdex 200 10/30 column, connected to fast protein liquid chromatography (FPLC) 
or to automatic ÄKTAprime™plus system, running buffer was buffer W, containing 1 
mM DDM. Applying 1 mM DDM detergent conserved the native trimeric (141.6 kDa) 
subunit of ecgltP (Gendreau et al., 2004). 
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2.3.6 SDS-PAGE analysis  
             
SDS-PAGE gel electrophoresis was performed using 12 % gels. Table 2.1 shows 
the constituents of the different solutions used for these gels. APS was prepared freshly 
as a 10 % solution in deionised H2O. The polymerisation of the running gel was allowed 
to proceed for about 30 minutes. After this the 3% stacking gel was poured. Gels were 
run in running buffer (25 mM Trisbase, 192 mM glycine and 3.5 mM SDS, pH 8.3), 
first at 100 V and when samples had entered the separation gel the voltage was 
increased to 180 V. 
 
Table 2.1 Constituents of the running and stacking gels of SDS gels. Protogel is an acrylamide-
bisacrylamide 37.5:1 mixture (Serva).  
 
Stock solution Running gel,
12 % 
Stock solution Stacking gel, 
3 % 
40 % Protogel  4 ml  7.5 % Protogel 650 µl 
1.5 M Tris, pH 8.8 2.5 ml  125 mM Tris-HCl, pH 6.8 1.2 ml 
10 % SDS 100 µl  10 % SDS 50 µl 
0.1 g/ml APS 100 µl  0.1 g/ml APS 25 µl 
TEMED 10 µl TEMED 5 µl 
SDS loading buffer (2x): 125 mM TrisHCl, 4.1 % SDS, 20 % glycerol, 200 mM DTT, 
0.014 mM bromphenol blue. 
 
2.4 Functional assays 
 
For functional tests ecgltP protein was reconstituted into artificial liposomes and 
transport was determined by measuring the accumulated radioactively labeled substrate 
inside the proteoliposome. 
 
2.4.1 ecgltP reconstitution protocol 
 
Reconstitution was performed essentially as described by Knol (Knol et al., 
1996). Liposomes were prepared from a n-pentane washed mixture of E. coli total Lipid 
Extract and L-α-phosphatidylcholine in 3:1 molar ratio in chloroform, dried under 
nitrogen and finally by vacuum to remove the chloroform. Lipids were resuspended in 
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buffer (50 mM KH2PO4, pH 7.0) to a final concentration of 20 mg of lipid per milliliter. 
The suspension was frozen in liquid nitrogen, thawed slowly and extruded through a 
400 nm polycarbonate membrane filter (Mayer et al., 1986) using Membrane Extruder 
for Laboratory (from Avestin Inc.). The liposomes thus obtained were diluted 6-fold in 
the same buffer and treated with increasing amounts of 10 % Triton X-100. The 
solubilization of the liposomes with Triton X-100 was followed by measuring the 
optical density at 540 nm (Rigaud et al., 1995) and the purified ecgltP was added (Fig. 
2.2). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Solubilization of liposomes. Treatment of the liposome solution with increasing amounts of 
10 % Triton X-100. The optical density was monitored at 540 nm.   
 
Unless otherwise stated, a protein/lipid ratio of 15 µg/mg was used. After 
addition of the purified protein, the mixture was rotated first at room temperature for 30 
minutes, after which proteoliposomes were formed by removal of the detergent by three 
successive extractions with Bio-Beads SM-2 Adsorbent™ polystyrene beads. The first 
extraction was performed at room temperature for 2 hours, and the second and third 
were at 4 °C for 2 hours and 16 hours, respectively. The beads were removed by 
filtration over glass wool, and the proteoliposomes were recovered by 
ultracentrifugation at 100,000 g for 30 minutes. The proteoliposomes were resuspended 
in the appropriate buffer and flash frozen in liquid nitrogen and stored at –80 °C until 
used.  
 
2.4.2 L-[3H]-glutamate / L-[3H]-aspartate uptake 
 
Assays of L-[3H]-glutamate / L-[3H]-aspartate uptake driven by artificial 
gradients were performed essentially as described by Konings group (Tolner et al., 
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1995b). For uptake experiments, to ensure a homogenous distribution of vesicle size, 
vesicles were frozen, thawed and subsequently extruded through the 400 nm 
polycarbonate membrane filter. Unless otherwise stated, the proteoliposomes were 
resuspended in buffer A (20 mM MES, 100 mM potassium acetate, 5 mM MgSO4, pH 
6.0). Uptake was measured at 22 °C. If necessary, temperatures were modified (Fig. 
3.15) by incubation in the Thermostat Plus system (Eppendorf). 
L-[3H]-glutamate / L-[3H]-aspartate uptake was initiated by diluting 25 μl of the 
proteoliposomes in 650 μl of buffer B (unless otherwise stated buffer B contains 
120mM MES, 100 mM NaOH, 5 mM MgSO4, and 0.0175 μM L-[3H]-glutamate or 
0.0175 μM L-[3H]-aspartate, pH 6.0). After the specified incubation periods, the 
samples were diluted in 1 ml of ice-cold stop solution (100 mM LiCl, 100 mM HEPES, 
pH 8.0) followed by immediate filtration over cellulose nitrate filters (pore size 0.45 
µm) from Sartorius. Filters were washed with an additional 3 ml of stop solution and 
were assayed for the presence of radioactivity and then measured using a liquid 
scintillation counter (TRICARB 2800 TR). Vesicles without protein were used in 
control experiments.  
 
Figure 2.3 Schematic demonstrations of ecgltP reconstitution in lipid vesicles and the uptake 
experiment. 
 
To study the underlying transport mechanism, the intra- and extravesicular ionic 
composition was modified. In all experiments, the intravesicular buffering capacity was 
increased by equimolar substitution of acetate with HEPES.  Buffers A and B were 
modified to study glutamate transport at different ionic conditions, and for clarity the 
conditions of each experiment are also shown schematically in the respective figures. 
The intravesicular solution was modified by several rounds of ultracentrifugation 
(100,000 g for 30 minutes), and resuspension of the proteoliposomes in solutions with 
differing composition and extrusion through a 400 nm polycarbonate membrane filter. 
[Na+] and [K+] concentrations were modified by equimolar substitution with NMDG. 
The pH was adjusted by replacing MES with the appropriate buffer hydroxides of the 
³H 
³H-L-glutamate /  
³H-L-aspartate  
variable conditions intravesicular substrate  
accumulation 
 2. Materials and methods 33 
major cations. In some of the experiments, intravesicular acetate was replaced with 
AMPSO, HEPES, or MES in order to increase the buffering capacity of the 
intravesicular solution.  
In the majority of experiments, to study the underlying transport mechanism the 
membrane potential of vesicle was modified by the addition of valinomycin to the 
vesicle suspension at a concentration of 2.5 µM, either in order to hyperpolarize the 
vesicles or to clamp their membrane potential to 0 mV. For static head experiments 
(Fukuhara et al., 1984; Turner, 1985) (Fig. 3.12), proteoliposomes were loaded with L-
[3H]-glutamate by incubation with 0.34 µM L-[3H]-glutamate at intra- and 
extravesicular 120 mM MES, 100 mM KOH, 5 mM MgSO4, 2.5 µM valinomycin, pH 
7.0 until reaching steady-state values. Control vesicles were formed in the same 
medium, containing 0.34 µM L-[3H]-glutamate, by repeated freezing, thawing, and final 
sonicating. The experiment was initiated by diluting the vesicles 1:9 in modified buffer 
B with pHs of 5.0, 6.0, 6.75, and 6.8, supplemented with 2.5 µM valinomycin.  
 
2.4.3 Data analysis 
 
Nonlinear regression fits of experimental and calculated data were performed 
using SigmaPlot (Systat Software, Inc). Each figure either shows means ± SEM from at 
least four samples of at least two separate experiments or a representative experiment 
that was performed at least four times. In each graph, data generated using at least two 
different proteoliposome preparations under different uptake conditions were compared. 
Transport rates were determined as inverse time constants from a fit of the time course 
of radioactive glutamate accumulation inside the vesicle with a monoexpontential 
function. The time constants were then converted into transport rates given as the 
number of glutamate molecules transported per second using the L-[3H]-glutamate 
calibration curve of scintillation counter. Dividing this value by the number of ecgltP 
monomers obtained from Bradford analysis resulted in unitary transport rates. 
Temperature coefficients (Q10) and apparent activation energies (EA) were extracted 
from individual transport rates using the Arrhenius equation:  
RTAEAeTv /)( −=  
where v is the initial transport rate at 0 s, T the temperature, R the gas constant, and A 
the constant factor. The Q10 was calculated from EA according to: 
Q10 = v(T+10K)/v(T) for T = 283  
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3.1 ecgltP protein purification  
 
ecgltP was cloned and overexpressed in E. coli. The membrane fraction was 
isolated from bacteria and purification was performed by one affinity chromatography 
step (Fig. 3.3 A). This resulted in a pure and homogenous population of trimeric ecgltP 
as shown by the results of size-exclusion chromatography (Fig. 3.3 B) and SDS PAGE 
analysis (Fig. 3.1, Fig. 3.2). 
     1    2     3      4     5     6     7     8     9    10    11         Lines: 
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Figure 3.1 Overexpression and purification of ecgltP. Coomassie staining of a 12 % SDS-PAGE gel. 
Lanes 5 and 18: molecular mass standard LMW (low molecular weight marker from GE Healthcare) is 
shown with the molecular weight in kDa. MW, molecular weight. 
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                       19   20   21    22   23                   
                                                              Lines:                      
                   
 
Figure 3.2 Purified ecgltP. Coomassie staining of a 12 % SDS-PAGE gel of strep-tagged ecgltP purified 
from E. coli. Lane 19: molecular mass standard LMW (low molecular weight marker from GE 
Healthcare) is shown with the molecular weights indicated in kDa. MW, molecular weight. A protein 
band can be seen at approximately 40 kDa, corresponding to monomeric ecgltP (Gendreau et al., 2004). 
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Figure 3.3 Affinity and size-exclusion chromatography elution profiles of ecgltP. (A) Monitoring at 
280 nm of different steps of the strep-tagged affinity chromatography purification using a Strep-
Tactin® Superflow® High Pressure column: (1) equilibration of the column, (2) loading of the protein 
containing sample, (3) washing step and (4) elution of the ecgltP protein. (B) Elution profile monitored at 
280 nm from size exclusion chromatography using a Superdex 200 column (24-ml bed volume). Vo, void 
volume, Alb., the elution volume of albumin (67 kDa). (A, B) Both columns were equilibrated with 1 mM 
DDM in Buffer W: 100 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, pH 8.0. 
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3.2 Purified and reconstituted ecgltP mediates substrate transport into 
proteoliposomes  
 
3.2.1 Glutamate accumulation by proteoliposomes containing purified ecgltP  
 
The time course of radioactive glutamate accumulation by proteoliposomes 
containing purified ecgltP in standard intravesicular and extravesicular solutions (see 
2.4.2) is shown in figure 3.4. At t = 0 min, the radioactive sample was applied and 
proteoliposomes containing ecgltP accumulated glutamate, reaching a steady state after 
40 min. A control experiment was carried out in parallel using vesicles without the 
ecgltP protein. Uptake into the control vesicles was negligible. Thus, reconstitution 
resulted in assembly of functional ecgltP in the artificial vesicular membranes. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Purified and reconstituted ecgltP mediates glutamate transport into liposomes. Time 
course (solid lines give fits to these time dependences with monoexponential functions) of L-[3H]-
glutamate accumulation in ecgltP-containing vesicles (z, n = 4) or control vesicles without protein (c, 
n≥ 4) at symmetrical potassium concentrations, pHo 6.0 and pHi 8.0, in the presence of valinomycin.  
 
The transport rates rise in a linear fashion dependent on the amount of 
reconstituted ecgltP present, from 2 to 10 µg/mg lipid (Fig. 3.5), indicating complete 
reconstitution of functional transporter in this range of protein/lipid ratios. Increased 
protein/lipid ratios result in larger percentages of vesicles containing at least one 
functional transporter and therefore an increased fraction of vesicles capable of 
accumulating L-[3H]-glutamate. This data indicate, that vesicular L-[3H]-glutamate 
accumulation is a specific result of glutamate transport by purified and reconstituted 
ecgltP.  
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3.2.2 Substrate specificity of ecgltP 
 
In order to test the specificity of the E. coli gltP-encoded glutamate transporter, 
the initial rates of L-[3H]-glutamate transport were determinate in the presence of other 
potential substrates, i.e. alanine, aspartate, cysteine, cystine, and serine (Fig. 3.6.) 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B
Figure 3.6 L-[3H]-glutamate uptake in the presence of various non-radioactive substrates at a 
concentration of 500 µM.  ecgltP (n ≥ 4),  control (n ≥ 4). L-[3H]-glutamate levels were 
measured after 10 min of incubation. 
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Fig. 3.5 Protein concentration-dependence of the transport rate (A) and accumulation (B) of L-[3H]-
glutamate into ecgltP proteoliposomes. In (B) accumulated L-[3H]-glutamate levels were measured after 
10 min of incubation (z, n = 3). 
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The radiotracer uptake is reduced in the presence of all potential substrates apart 
from D-alanine (p < 0.01), indicating competition between these compounds and 3H-L-
glutamate. A decrease comparable to the effect of non-radiolabeled L-glutamate was 
only observed for L-aspartate. A non-related neurotransmitter, dopamine, did not cause 
a significant reduction of radioactive glutamate fluxes, indicating a specific substrate 
transport by ecgltP.  
In addition, the vesicular uptake of L-serine and of dopamine as a negative 
control was studied using radiotracer flux measurements directly (Fig. 3.7). In contrast 
to mammalian EAATs (Bendahan et al., 2000), ecgltP does transport L-[14C]-serine, but 
in comparison to L-glutamate the serin transport is strongly reduced. Transport of 
radioactively labeled dopamine was not observed.  
 
 
 
3.3 Cation selectivity of ecgltP 
3.3.1 Glutamate uptake by ecgltP is sodium- and potassium-independent 
Secondary-active transport utilizes transmembrane voltage and ion gradients. 
Eukaryotic glutamate transporters carry one glutamate molecule together with three Na+ 
ions and one H+ in counter-transport with one K+ ion, resulting in the movement of two 
net charges per transport cycle (Levy et al., 1998; Zerangue et al., 1996). To assess the 
coupling ratio of Na+ or K+ to glutamate transport by ecgltP, 3H-L-glutamate uptake in 
the presence of varying Na+ or K+ concentrations was measured. In contrast to 
mammalian EAATs, variation of neither the external [Na+] nor the intravesicular [K+] 
Figure 3.7 Uptake levels of 0.0175 µM L-[3H]-glutamate, L-[14C]-serine and [3H]-dopamine. 
ecgltP (n = 4),  control (n = 4). Accumulated radioactivity levels were measured after 10 min. 
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modifies equilibrium glutamate uptake by ecgltP (Fig. 3.8 A and B). A discrepancy in 
the uptake levels between (A) and (B) may be due to the presence of N-methyl-D-
glucamine (see 2.4.2), which may have some influence on transport, as has been shown 
for GltPh (Ryan et al., 2009).  
According to these results, it is possible to conclude that there is no change of 
transport activity under these conditions, indicating that the transport is not coupled to 
other cations beside protons.  
     
 
 
 
 
 
Figure 3.8 L-[3H]-glutamate uptake at various concentrations of extravesicular Na+ (A) or 
intravesicular K+ (B). Accumulated L-[3H]-glutamate levels were measured after 10 min (n = 4). 
Standard intra- and extravesicular solutions with symmetrical pH, without addition of valinomycin.  
 
 
3.3.2 ecgltP co-transports glutamate and H+ 
 
Glutamate transport by the EAATs is also coupled to the co-transport of one 
proton (Zerangue et al., 1996). To test if transport by ecgltP is similarly coupled to H+, 
3H-L-glutamate uptake in the presence of two different pH-gradients was measured 
(Fig. 3.9).  
ecgltP-mediated glutamate uptake is dependent on the proton gradient, for two 
different external pHs. The application of an intravesicular pH (pHi) of 8.0 and an 
external pH (pHo) of 6.0 causes a fast glutamate accumulation that reaches equilibrium 
at higher internal L-[3H]-glutamate concentrations than for an external pH of 7.0. Thus, 
acidic pH stimulates glutamate transport and increases the steady-state concentration, 
indicating that ecgltP mediates a coupled transport of one glutamate and at least one 
proton.  
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Figure 3.9 ecgltP-mediated glutamate uptake is dependent on the proton gradient, for two different 
external pHs. pH dependence of the time course of L-[3H]-glutamate accumulation into ecgltP-
containing proteoliposomes at pHi 8.0 in the presence of valinomycin, (n = 4). 
 
3.4 Determination of the transport stoichiometry of ecgltP  
 
3.4.1 Electrogenecity of glutamate transport by ecgltP 
 
Was tested, if ecgltP-mediated L-glutamate transport is an electrogenic process. 
For this purpose the vesicular membrane potential was modified by the addition of 
valinomycin and the establishment of a potassium gradient across the vesicle 
membrane. Valinomycin (Fig. 3.10) is a highly selective potassium ionophore. 
Therefore, the application of symmetrical potassium and valinomycin concentrations 
clamped the membrane potential of the vesicles to 0 mV, and the application of 
potassium internally but not externally, in presence of valinomycin hyperpolarizes the 
vesicle. 
 
  
Figure 3.10 Valinomycin structure. (A) Primary structure of valinomycin. (B) Crystal structure of the free 
valinomycin. (C) Crystal structure of the potassium complex of valinomycin. 
A C B 
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Figure 3.11 Glutamate transport by ecgltP is electrogenic.  Time course of the L-[3H]-glutamate 
uptake at two different vesicular potentials, in the presence or absence of valinomycin, at pHi = 6.0 and 
pHo = 6.0.  
 
With a K+-free external solution, permeabilization of the liposomes with 
valinomycin causes a passive efflux of K+ and hyperpolarizes the vesicle interior. At a 
symmetrical pH of 6.0, such a process results in increases in both the speed of uptake 
and steady state level of the radioactive glutamate (Fig. 3.11). The conclusion is that 
glutamate uptake is associated with the movement of positive charges across the 
membrane. Since glutamate is negatively charged, glutamate transport must be coupled 
to the movement of at least two protons.  
 
3.4.2 Determination of the coupling stoichiometry of ecgltP by the static head method 
 
H+/glutamate symport terminates when the electrochemical gradients for protons 
and glutamate compensate for each other. The relationship between the equilibrium 
concentrations is given by equation (1): 
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Where V represents the transmembrane voltage and n the transport stoichiometry 
or coupling coefficient, i.e. the number of H+ coupled to the transport of one glutamate. 
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In a semilogarithmic plot, this equation predicts a linear relationship between the 
accumulated radioactivity and the calculated transmembrane potential, with a slope of 
n–1. 
Next, to determine the coupling coefficient the static head method was employed 
(Fukuhara et al., 1984; Turner, 1985), see also 2.4.2. Vesicles were first loaded with L-
[3H]-glutamate and kept in an external medium with the same concentration of labeled 
glutamate as in the loaded vesicles. After establishing an outwardly directed 1:10 
glutamate gradient by 1:9 dilution into solutions with variable pHs, the change of 
intravesicular L-[3H]-glutamate concentration over time was measured (Fig. 3.12 A). In 
these experiments, vesicles were clamped to 0 mV using symmetrical K+ and 
valinomycin.  
The net substrate flux depends on the glutamate and the proton gradients and 
will be zero at ionic conditions at which the driving force for the coupled transport is 
zero:   
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glutamate
glutamate −=                      (3) 
 
Under the conditions applied here, this can be simplified to: 
 
1)( =− oi pHpHn                         (4) 
 
At an extravesicular pH of 6.0, glutamate is transported into the vesicles, 
whereas glutamate moves out of the vesicle at a pHo of 6.8 (Fig. 3.12 A). Glutamate 
transport by ecgltP is very slow under these conditions, preventing an accurate 
determination of the time constants and steady-state values of intravesicular glutamate 
concentrations. However, vesicular glutamate concentrations obtained in this 
experiment allow determination of the pH at which the H+/glutamate transport is at 
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equilibrium. Figure 3.12 (B) gives the normalized glutamate accumulation on a 
logarithmic scale for three different pHo values 20 minutes after dilution of the vesicles. 
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Figure 3.12 Static head experiment. (A) Time course of the normalized intravesicular L-[3H]-glutamate 
concentration at three external pHs after 1:9 dilution in a static head experiment. (B) Plot of the vesicular 
L-[3H]-glutamate, measured 20 min after dilution, from the experiments shown in (A), versus the external 
pHs. The solid line gives mean values from control vesicles, the dashed lines control mean values ± SEM.  
 
The pH dependence is well described by a straight line that crosses the x-axis at 
pH 6.67. Measurements 10 min after dilution produced similar results (data not shown), 
indicating that H+/glutamate symport is at equilibrium at pH 6.67. The conclusion is 
that, under the tested experimental conditions, ecgltP sustains a coupled transport of 
three protons and one glutamate.  
 
3.4.3 Determination of the coupling stoichiometry of ecgltP by voltage dependence 
measurements  
 
In order to determine the coupling stoichiometry of the H+/glutamate symport, 
the glutamate uptake was compared at different membrane potentials. Vesicular 
potentials were modified by variation of the extravesicular K+ concentration in the 
presence of 2.5 µM valinomycin, to produce potentials of –20 mV, –37 mV, and –50 
mV. Reduction of [K+]o resulted in increased uptake rates and steady state glutamate 
accumulations after 40 min of incubation. The voltage dependence of glutamate 
transport (Fig. 3.13) allowed the determination of the number of protons that are co-
transported with one glutamate by ecgltP.  
A B
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Figure 3.13 Voltage dependence of glutamate transport by ecgltP. Vertical bars show the accumulated 
glutamate at steady state, after 40 min of incubation at different voltages (n = 4), ecgltP. 
 
For a coupled transporter that only transports protons and glutamate, as is the 
case for ecgltP, the ratio of intravesicular glutamate to extravesicular glutamate depends 
on the transmembrane proton gradient and voltage (equation 1, see 3.4.2). This 
relationship can be expressed using a logarithmic plot of the intravesicular glutamate 
concentration versus the transmembrane voltage. The linear fit (Fig. 3.14) to this 
relationship (equation 1) gives the number of co-transported protons. The red lines show 
the predicted glutamate accumulation, assuming a coupling ratio of 3 or 2 co-
transported protons. The voltage dependence of the accumulated glutamate 
concentration reveals that three protons are co-transported with one glutamate by 
ecgltP. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14 Coupling stoichiometry of ecgltP. Predicted glutamate accumulation assuming a coupling 
ratio of 3 or 2 co-transported protons (red lines), (z) plotted from Fig. 3.13 data of the voltage 
dependence of glutamate transport by ecgltP.  
 
 3. Results 46 
 
Time (min)
0 10 20 30 40L
-g
lu
ta
m
at
e 
(p
m
ol
/m
g 
pr
ot
ei
n)
0
20
40
60
 4 oC
15 oC
25 oC
K+
pH 8.0
Na+
pH 6.0
valinomycin
3.5 Temperature dependence of ecgltP-mediated glutamate uptake  
 
Active transport mechanisms are processes, which are required for the uphill 
movement of substrates. Temperature coefficients (Q10) and apparent activation 
energies (EA) are obtainable by extraction from individual transport rates using the 
Arrhenius equation (see also 2.5.4). For this purpose, the rate of glutamate accumulation 
at various temperatures (Fig. 3.15) was measured. Under described conditions 
experiments indicate that the uptake rates increase with temperature with a Q10 of 8. An 
Arrhenius plot of transport rates with hyperpolarized vesicular potentials (Fig. 3.16), 
demonstrates that glutamate transport is associated with an apparent activation energy 
of 160 kJ/mol.  
                                  
 
 
 
 
 
 
 
 
 
Figure 3.15 Temperature dependence of ecgltP glutamate transport. Time course of L-[3H]-glutamate 
accumulation in vesicles at three different temperatures z 4 °C (n = 4), c 15 °C (n = 4), and T 25 °C (n 
= 4).  
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Figure 3.16 Arrhenius plot for initial transport rates. Plot based on data shown in Fig. 3.15. 
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3.6 Characterization of N401D ecgltP 
 
3.6.1 N401D ecgltP mediates glutamate/aspartate transport into liposomes  
 
 N401D ecgltP contains an aspartate residue at a position homologous to D405 of 
GltPh, which was shown to be crucial for sodium binding (Boudker et al., 2007). The 
time course of radioactive glutamate accumulation by proteoliposomes containing 
purified N401D ecgltP in standard intravesicular and extravesicular solutions (see 2.4.2) 
is shown in Fig. 3.17 A. Control experiment was carried out in parallel using vesicles 
without the ecgltP protein. Because N401D ecgltP dramatically reduces the transport 
rate of L-glutamate (Fig. 3.17), for the following experiments L-aspartate with a higher 
transport rate was used as a substrate. Furthermore, in order to get uptake rates of 
N401D ecgltP significantly above the control level, it was also necessary to modify the 
membrane potential and to increase a protein/lipid ratio to 45 µg/mg (2.4.1). Figure 3.17 
B shows values of the accumulated radioactivity after 40 min of incubation for WT 
ecgltP and N401D ecgltP with two different substrates (glutamate or aspartate). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17 Substrate transport into proteoliposomes via N401D ecgltP.  (A) Time courses of the L-
[3H]-glutamate uptake at negative vesicular potentials, in the presence of valinomycin, at symmetrycal pH 
= 6.0. (T) WT ecgltP (n = 3), (c) N401D ecgltP (n = 2), and (z) control were vesicles without protein 
(n = 4). A protein/lipid ratio of 15 µg/mg for WT ecgltP and N401D ecgltP was used. (B) Graphs show 
values of the accumulated radioactivity after 40 min of incubation with two different substrates, WT 
ecgltP (n = 4) and N401D ecgltP (n = 4). Control uptake values were substracted. Protein/lipid ratios of 
15 µg/mg for WT ecgltP and 45 µg/mg for N401D ecgltP were used. 
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3.6.2 N401D ecgltP mediates electrogenic co-transport of substrate and protons 
 
To test if transport by N401D ecgltP is similarly coupled to H+ as by WT ecgltP, 
3H-L-aspartate uptake in the presence of various pH-gradients was performed (Fig. 
3.18). N401D ecgltP-mediated glutamate uptake is dependent on the proton gradient. 
The application of an intravesicular pH of 6.0 and an external pH of 6.0 causes a fast 
glutamate accumulation that reaches equilibrium at higher internal L-[3H]-aspartate 
concentrations than for other external pHs. Again, acidic pH stimulates substrate 
transport and increases the steady-state concentration, indicating that N401D ecgltP 
mediates a coupled transport of one glutamate and at least one proton.  
 
 
             
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18 N401D ecgltP co-transports aspartate and H+. pH dependence of the time course of L-
[3H]-aspartate accumulation in N401D ecgltP-containing proteoliposomes at pHi 8.0, in the presence of 
valinomycin, vesicles without protein were used as a control (n = 3). 
 
 
Glutamate transport by WT ecgltP is electrogenic. In order to determinate, if 
N401D ecgltP-mediated substrate transport is also an electrogenic process following 
experiments were performed. Figure 3.20 shows time courses of the accumulated 
glutamate at different voltages. Vesicles without protein were used as a control. Data 
demonstrate, that substrate transport via N401D ecgltP is also an electogenic process. 
Since aspartate carriers a net single negative charge, the aspartate co-transport via 
N401D ecgltP must be coupled to the movement of at least two positive charges. 
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3.6.3 Aspartate uptake by N401D ecgltP is Na+-independent 
 
This mutant was designed with the expectation of finding a sodium dependent 
transport mechanism, lacking in the WT ecgltP. However, aspartate uptake by N401D 
ecgltP is sodium independent (Fig. 3.19). This indicates that the negative charge that is 
found in the homologous position in GltPh is not alone responsible for Na+-coupling. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.19 L-[3H]-aspartate uptake via N401D ecgltP at various concentrations of extravesicular 
Na+. Standard intra- and extravesicular solutions with symmetrical pH and 2.5 µM valinomycin were 
applied. Accumulated L-[3H]-aspartate levels were measured after 40 min (n = 4). 
 
 
3.6.4 Determination of the coupling stoichiometry of N401D ecgltP by voltage 
dependence measurements  
 
As was shown for the wild type ecgltP (Fig. 3.13 and 3.14), voltage dependence 
of glutamate transport allowed the determination of the number of protons that are co-
transported with one glutamate by N401D ecgltP. In order to determine the coupling 
stoichiometry of the H+/glutamate symport via N401D ecgltP the same method of 
voltage dependence measurements (see also 3.4.3) was applied (Fig. 3.20, Fig. 3.21). 
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Figure 3.20 The voltage dependence of glutamate transport by N401D ecgltP. Time courses of the 
accumulated glutamate at different voltages are demonstrated (n = 4). 
 
 
 
 
Figure 3.21 Coupling stoichiometry of WT ecgltP and N401D ecgltP.  Predicted glutamate 
accumulation assuming a coupling ratio of 3 or 2 co-transported protons (red lines). Plotted data of the 
voltage dependence at steady state (after 40 min of incubation) of glutamate transport by WT ecgltP 
(from Fig. 3.13) and by N401D ecgltP (from Fig. 3.20). 
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The voltage dependence of the glutamate accumulation by N401D ecgltP reveals 
that, in contrast to the wild type, the mutant transports one glutamate stoichiometrically 
coupled to two protons. Obviously, N401 residue plays a role in defining the number of 
co-transported protons in ecgltP. 
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4. Discussion 
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Glutamate transport proteins play a crucial role in both eukaryotic and 
prokaryotic cells. Although their functions in both kingdoms are very different, the 
correlation of the conclusions from mutagenesis experiments on eukaryotic glutamate 
transporters with the high-resolution structure of a prokaryotic glutamate transporter 
GltPh from Pyrococcus horikoshii indicates that eukaryotic and prokaryotic glutamate 
transporters share a common architecture, sequence, oligomerisation state, structure, 
and basic mechanism of transport. However, little is known about the functional 
mechanisms of the prokaryotic transporters. The gltP gene of Escherichia coli encodes a 
protein homologous to the mammalian EAAT-type glutamate transporters. The study of 
ecgltP allows the application of molecular, functional, and biochemical methods to 
elucidate the molecular mechanisms underlying coupled transport by this glutamate 
transporter. The transport mechanisms determined for ecgltP may be similar to those in 
its eukaryotic homologues, and thus it may be possible to extrapolate from the 
information obtained in this study to gain a better understanding of the molecular 
determinants of coupled transport by eukaryotic glutamate transporters. In this thesis, a 
detailed functional characterization of ecgltP is presented, where the ion dependence of 
this glutamate transporter is described. Like the EAATs, glutamate transport by ecgltP 
is coupled to the co-transport of H+. In contrast to the EAATs, this process is not 
coupled to the co-transport of Na+ ions or the counter-transport of K+ ions. 
 
4.1 Purified and reconstituted ecgltP mediates glutamate uptake into 
proteoliposomes  
 
After expression in E. coli, ecgltP was purified by one affinity chromatography 
step from bacteria and than eluted predominantly as a single symmetrical peak (Fig. 3.3 
B), indicating that the majority of the purified protein (>95 %) exists in one oligomeric 
conformation. The use of 1 mM DDM detergent in the protein purification procedure 
conserves the native trimeric subunit stoichiometry of ecgltP (Gendreau et al., 2004). 
Purified ecgltP was reconstituted in artificial lipid vesicles. Radiotracer flux 
measurements into ecgltP-containing proteoliposomes were then used to characterize 
the transport properties of ecgltP. Reconstitution experiments demonstrated that ecgltP 
was able to sustain coupled transport. The dependence of L-[3H]-glutamate 
accumulation – determined after 10 min – on the protein/lipid ratio is well described by 
a mono-exponential function (Fig. 3.5 B), as expected for a Poisson distribution 
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(Heginbotham et al., 1998). It was shown that glutamate transport by ecgltP is 
electrogenic (Fig. 3.11 A, Fig. 3.11 B) and depends only on the proton concentrations 
on both sides of the membrane (Fig. 3.9), but is not affected by the presence, absence or 
concentration of Na+ (Fig. 3.8 A) or K+ (Fig. 3.8 B). ecgltP has already been studied 
using radiotracer flux experiments with cytoplasmic bacterial membrane vesicles or 
whole bacteria cells after the overexpression in E. coli (Deguchi et al., 1989; Wallace et 
al., 1990). In both reports, as well as in this work, a sodium-independent, electrogenic 
uptake of glutamate was reported. The conditions of protein purification and 
reconstitution and the method of performing the functional tests therefore do not modify 
the transport properties of ecgltP. The techniques used in the work presented here 
allowed the study of ecgltP in artificial liposomes without possible contamination by 
other cellular components.  
 
4.2 ecgltP has less substrate specificity than eukaryotic EAAT glutamate 
transporters 
 
ecgltP is mainly selective for glutamate and aspartate (Fig. 3.6, Fig. 3.7) but also 
sustains a secondary-active transport for alanine, cysteine, cystine, and serine, albeit 
with a lower affectivity. This property contrasts with the specificity of the EAAT 
glutamate transporters (Danbolt, 2001).  
This difference between prokaryote and eukaryote substrate specificity makes 
sense in light of the fact that glutamate transporter function in both kingdoms is 
different. Little is known about the biological function of ecgltP but one may speculate 
that the reason for such a broad spectrum of transported substrates, is that as bacterial 
glutamate transporter proteins are nutrition transporters, it is beneficial for the bacteria 
not only to accumulate glutamate (Halpern et al., 1965) but also other amino acids. 
 
4.3 Stoichiometry of ecgltP: three protons are electrogenically co-transported with 
one glutamate 
 
In marked contrast to mammalian glutamate transporters and to some other 
bacterial glutamate transporters, transport by ecgltP does not depend on sodium (Fig. 
3.8 A) or potassium (Fig. 3.8 B). Glutamate transport by purified ecgltP is therefore not 
energetically coupled to the movement of these ions, in agreement with earlier results 
 4. Discussion 55 
on cytoplasmic bacterial membranes and on whole bacteria (Deguchi et al., 1989; 
Wallace et al., 1990) or on purified and reconstitution in E. coli lipids glutamate 
transporter GltT from Bacillus stearothermophilus (Gaillard et al., 1996). GltT-
mediated glutamate transport has also been reported as independent of external [Na+]. 
The results presented here demonstrate that ecgltP-mediated H+:glutamate co-
transport is electrogenic (Fig. 3.11), with a coupling stoichiometry of 3:1 (Fig. 3.12, 
Fig. 3.14). Two different methods were applied to determine the coupling stoichiometry 
of ecgltP: the static head method (Fukuhara et al., 1984; Turner, 1985) and 
measurements of the voltage dependency of accumulated substrate at the steady state. 
Both techniques produced the same result and showed that three protons are co-
transported together with one glutamate by ecgltP, demonstrating that the properties of 
Na+ co-transport and K+ counter-transport with glutamate are not conserved between 
evolutionarily distant members of the glutamate transporter family: ecgltP and EAATs. 
This is especially interesting because ecgltP lacks a glutamate residue at position 
320. In GLT-1, the rat homolog of EAAT2, a glutamate residue at the equivalent 
position (E404) was proposed to bind K+ (Kavanaugh et al., 1997). The demonstrated 
K+-independence of glutamate transport via ecgltP and the absence of this residue in 
ecgltP are consistent with that proposed role of this glutamate residue as a K+ acceptor. 
On the other hand, in another isoform – EAAT3 – the same residue was proposed to be 
responsible for H+ binding (Grewer et al., 2003). ecgltP transports three protons without 
having a glutamate residue at this position, demonstrating that this binding site is not 
conserved between mammalian and prokaryotic  glutamate transporters. 
 
4.4 Determination of unitary transport rates and temperature dependence of 
ecgltP-mediated glutamate uptake  
 
Secondary-active transporters are usually thought to function using an 
alternating access mechanism (Jardetzky, 1966; Kavanaugh, 1998). In this canonical 
transport scheme, one or more permeation pathways possess gates at the intra- and 
extracellular sides of the plasma membrane. These gates are never simultaneously open, 
but instead open sequentially to allow alternating access to the cytoplasmic and 
extracellular compartments. An alternative mechanism for secondary-active transport is 
one in which multiply-occupied channels contain a variety of substrates moving in 
single-file (Läuger, 1979; Läuger, 1980; Su et al., 1996; DeFelice et al., 2001). In such 
 4. Discussion 56 
transport processes, ions move when another ion enters the pore from either direction, 
and this coupling of substrate transport is capable of sustaining the channel-mediated 
transport of one substrate against its electrochemical gradient. Alternating access and 
channel-like transporters differ in their transport rates and in the conformational 
changes necessary for substrate transport. In this study, the unitary transport rates and 
the temperature dependence of ecgltP-mediated glutamate transport were therefore 
determined to define the mechanism used by the ecgltP transporter (see 2.4.3 and 3.5). 
The ecgltP transporter consists of three subunits (Gendreau et al., 2004), each of 
which has been shown to be able to transport glutamate independently (Yernool et al., 
2004; Grewer et al., 2005; Koch et al., 2005). Time course measurements of radioactive 
glutamate accumulation and the calculation of the number of ecgltP subunits present in 
the tested vesicle sample, yielded an estimate of a transport rate of 4 glutamate 
molecules/sec at 0 mV vesicle potential and of 62 molecules/sec for a hyperpolarized 
membrane potential achieved by adding valinomycin to a K+-free external solution. This 
is closely similar to the values for mammalian EAAT glutamate transporters of 1.3 
molecules s-1 for purified rat glutamate transporters (Danbolt et al., 1990) and between 
4 and 27 molecules s-1 for human EAAT2 heterologously expressed in Xenopus oocytes 
(Wadiche et al., 1995).   
Measurements of ecgltP uptake were performed at different temperatures (4 °C, 
15 °C and 25 °C) (Fig. 3.15). Based on this data an Arrhenius plot (see 2.4.3., 3.5 and 
Fig. 3.16) of transport rates with hyperpolarized vesicular potentials demonstrates that 
glutamate transport is associated with an apparent activation energy of 160 kJ/mol. The 
apparent activation energy of glutamate transport is much larger than values 
characteristic for diffusion-limited processes (Hille, 1992) and strongly supports a 
transport mechanism that involves large conformational changes of the transport 
protein. Measurements of individual transport rates and their temperature dependence 
indicated a transport process that encompasses major conformational changes, 
consistent with alternating access models. Glutamate transport by ecgltP can therefore 
be considered to be associated with major conformational changes of the protein and 
resembles transport by mammalian homologues in general.  
The temperature dependence data and measurements of individual transport rates 
support the notion that conformational changes are associated with the ecgltP transport 
mechanism, which is also in agreement with the results of functional characterization of 
GltPh (Ryan et al., 2009). 
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4.5 Characterization of N401D ecgltP 
 
The aspartate at position 405 of GltPh and the homologous residues in other 
glutamate transporters are known to bind Na+ during the glutamate transport process 
(Tao et al., 2006, Tao et al., 2007; Boudker et al., 2007). In wild type ecgltP, this 
residue is exchanged to asparagine. To elucidate the role of this residue in ecgltP, a 
mutant – N401D ecgltP – bearing the conserved aspartate at this position was studied.  
Transport by N401D ecgltP does not depend on sodium (Fig. 3.19). This finding 
demonstrates that coupling of glutamate and Na+ transport cannot be transplanted from 
mammalian EAATs, or from GltPh to ecgltP by inserting a single negative charge and 
also that other amino acids take part in Na+ transport and that the molecular 
requirements for coupled sodium-glutamate transport are more complex than currently 
thought.  
The voltage dependency of the glutamate accumulation by the N401D ecgltP 
mutant reveals that, in contrast to the wild type ecgltP, which mediates the 
stoichiometrically coupled co-transport of one glutamate and three protons, N401D 
ecgltP presents voltage-dependent transport of one glutamate stoichiometrically coupled 
to two protons (Fig. 3.20, Fig. 3.21). 
Surprisingly, instead of changing the glutamate transport to a Na+-dependent 
mechanism the introduction of aspartate at this position (N401) altered the H+:glutamate 
transport stoichiometry to 2:1. Moreover, N401 plays an additional role in defining the 
number of co-transported protons in ecgltP. It appears possible that D401 acts as a 
possible binding site for protons. One could imagine that the incorporated aspartate 
increases affinity for one proton. The proton can no longer dissociate, but remains 
bound and is therefore not transported.  
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4.6 Conclusions 
 
The functional characterization of ecgltP transporter presented in this study 
demonstrates that: 
 
 
• Na+ co-transport and K+ counter-transport are not conserved between ecgltP and 
EAATs. 
 
• ecgltP mediated H+:glutamate co-transport has a coupling stoichiometry of 3:1. 
 
• substantial conformational changes are associated with ecgltP transport function, 
supporting an alternating access model. 
 
• residue N401 plays a role in defining the number of co-transported protons in 
ecgltP. 
 
• coupling of glutamate and Na+ transport can not be transplanted to ecgltP by 
inserting a single negative charge at position 401. 
 
• ecgltP represents a model to study the mechanisms underlying glutamate transport 
and coupled transport in general. The existence of such a protein model provides a 
good system to test hypotheses concerning different steps in the glutamate uptake 
cycle.  
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4.7 Further research 
 
Glutamate transporter proteins are still incompletely understood. The bacterial 
glutamate transporter from E. coli – ecgltP – represents an interesting model to study 
glutamate transport. A complete understanding of Na+- and K+-binding sites in 
mammalian isoforms could potentially be achieved by transferring these sites to ecgltP 
mutants. Performing such experiments using ecgltP would thus help future 
understanding of coupled transport in EAATs. 
In addition, interesting questions are still open regarding the oligomerisation 
state of the protein and its influence on the mechanism of glutamate uptake. The ecgltP 
transporter consists of three subunits (Gendreau et al., 2004) each of which are able to 
transport glutamate independently (Yernool et al., 2004; Grewer et al., 2005; Koch et 
al., 2005). The detergent DDM conserves the native trimeric subunit stoichiometry 
(Gendreau et al., 2004), while LDAO disrupts this assembly and produces a 
monodispersed fraction of monomeric ecgltP. Producing by applying of different 
detergents in purification procedure or by mutagenesis and comparing functional 
properties of the two types of ecgltP transporters – trimers and monomers – could give 
information about the impact of oligomerisation on transport functions.  
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5.1 Abstract, English 
 
Functional characterization of a glutamate transporter from Escherichia coli 
 
Glutamate is the major excitatory neurotransmitter in the mammalian CNS. 
After its release from glutamatergic nerve terminals, glutamate is rapidly taken up into 
glial and neuronal cells by mammalian Na+-dependent glutamate transporters 
(excitatory amino acid transporters 1 to 5, EAATs). In recent years, various EAAT 
paralogs have been identified in prokaryotes and shown to exhibit different transport 
stoichiometries. Whereas EAATs transport 3 Na+, 1 H+, and 1 glutamate in 
countertransport with 1 K+, there are bacterial paralogs that only transport 
glutamate/aspartate stoichiometrically coupled to H+, or to Na+. The simplicity of the 
transport stoichiometry of bacterial transporters might allow transplantation of transport 
mechanisms from one isoform to the other and thus provide insights into molecular 
determinants of coupled transport. Radiotracer flux accumulation by purified and 
reconstituted glutamate transporter from E. coli (ecgltP) was studied. In marked contrast 
to mammalian EAATs, glutamate transport by ecgltP is independent of Na+ and K+. 
ecgltP transports H+ and glutamate, and the voltage dependence of radiotracer flux 
accumulation allowed the determination of a transport stoichiometry of one glutamate 
coupled to three protons. Measurements of individual transport rates of ecgltP and their 
temperature dependence demonstrated a transport process that encompasses major 
conformational changes, consistent with alternating access models. WT ecgltP was 
characterized in comparison to the N401D ecgltP mutation. In sodium-dependent 
aspartate transporters, a conserved aspartate in TM8 (D405 in GltPh) is known to bind 
Na+ during the glutamate transport process. In ecgltP an asparagine is present instead of 
aspartate. Insertion of this candidate binding site into ecgltP does not convert this into a 
sodium-coupled glutamate transporter. It solely reduces the number of cotransported 
protons from 3 to 2. This finding demonstrates that coupling of glutamate and Na+ 
transport cannot be transplanted from mammalian EAATs to ecgltP by inserting a single 
negative charge and also that other amino acids take part in Na+ transport and that the 
molecular requirements for coupled sodium-glutamate transport are more complex than 
currently thought.  
 
Keywords: 
glutamate transporters, ecgltP, EAATs 
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5.2 Zusammenfassung 
 
Funktionelle  Charakterisierung eines Glutamattransporters aus Escherichia coli 
 
Die Aminosäure L-Glutamat ist der wichtigste exzitatorische Neurotransmitter 
im zentralen Nervensystem von Säugetieren. Glutamat wird nach der Freisetzung aus 
glutamatergen Nervenendigungen durch Natrium abhängige exzitatorische 
Aminosäuretransporter (excitatory amino acid transporters 1-5, EAAT) in gliale und 
neuronale Zellen aufgenommen. In den vergangenen Jahren wurden in Prokaryoten 
verschiedene EAAT Paraloge identifiziert, die sich in der Transportstöchiometrie von 
Säugetierisoformen unterscheiden. Während eukaryotische Transporter (EAATs) drei 
Natriumionen, ein Proton und ein Glutamat im Gegentransport mit einem Kaliumion 
transportieren, ist in prokaryotischen Transportern der Transport eines Glutamats / 
Aspartats nur an Protonen oder nur an Natriumionen gekoppelt. 
In dieser Studie wurde ein Glutamattransporter aus E. coli  (ecgltP) mit Hilfe 
von Radiotracerflux-Techniken untersucht. EcgltP transportiert Glutamat zusammen mit 
Protonen. Aus der Spannungsabhängigkeit der Glutamatakkumulation konnte ein 
Kopplungskoeffizient von einem Glutamat zu drei Protonen bestimmt werden. Um die 
molekularen Determinanten des gekoppelten Transports besser zu verstehen, wurde eine 
potenzielle Natriumbindungsseite aus eukaryotischen Transportern in ecgltP imitiert. 
EcgltP unterscheidet sich u.a. in dieser potenziellen Natriumbindungsstelle von 
natriumabhängigen Glutamattransportern. Die Modifikation dieses potenziellen 
Bindungsplatzes durch eine Punktmutation (N401D) ist jedoch nicht ausreichend für 
einen natriumgekoppelten Glutamattransport in ecgltP. N401D ecgltP weist weiterhin 
eine Natrium-unabhängige Stöchiometrie mit einem Glutamat und zwei Protonen auf. 
Dies zeigt, dass ecgltP, auch wenn alle bekannten Natriumbindungsplätze durch 
molekulare Modifikationen vorhanden sind, immer noch keine Natriumionen 
transportieren kann, und dass die molekularen Anforderungen für den gekoppelten 
Natrium-Glutamat-Transport  komplexer sind, als bisher angenommen. 
 
Stichwörter: 
Glutamattransporter, ecgltP, EAATs 
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7. Supplemental Information  
 
Table 7.1 Members of the of the DAACS family. From Slotboom et al., 1999. 
 
Table 7.2 Score Table of three distantly related glutamate transporters GltPh, ecgltP, and hEAAT2. 
The table is based on a multiple amino acid sequence alignment using ClustalW (Chenna et al., 2003). 
Abbreviations: glutamate transporter from archaebacteria P. horikoshii (GltPh), bacterial glutamate 
transporter from E.  coli (ecgltP), and human isoform of excitatory amino acid transporters (hEAAT2). 
 
SeqA Name     Len(aa)  SeqB Name     Len(aa)  Score 
=================================================== 
1    GltPh    425      2    ecgltP   437      33    
1    GltPh    425      3    hEAAT2   574      32    
2    ecgltP   437      3    hEAAT2   574      26    
=================================================== 
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Table 7.3 List of equipment and materials used. 
 
Equipment / Consumption items Company 
Agarose gel system PEQLAB Biotechnologie GMBH  
Amicon Ultra (Ultracel 30 k) Millipore 
Autoclave Systec D-150 Systec GmbH 
Affinity chromatography:  
ÄKTAprime™plus system  GE Healthcare Bio-Sciences  
Strep-Tactin® Superflow® High Pressure column IBA 
Cellulose nitrate filter (0.45 µm) Sartorius Biolab Products 
Cuvettes:  
             Cuvettes REF 67.742 Sarstedt 
             UVette 220-1600 nm Eppendorf 
Centrifuges:         
             Rotanta 460R Heraeus Fresco 17 centrifuge Thermo Scientific 
             Micro centrifuge MiniSpin®  Eppendorf 
             Table centrifuge 5415C  Eppendorf 
             Avanti™ J-25 centrifuge Beckman Coulter, Inc. 
             Ultracentrifuge Optima™ LE-80k Beckman Coulter, Inc. 
             Rotors for the ultracentrifuge: 70 Ti.1, SW-41 TI Beckman Coulter, Inc. 
Centrifuge tubes (15 ml, 30 ml, 50 ml)  Beckman Coulter, Inc. 
Centrifuge tubes (15 ml, 30 ml, 50 ml)  G. Kisker GbR 
Glass microfiber filters 934-AH™ Whatman  
Fast protein liquid chromatography (FPLC) system:  
Superdex column 200 – 10/30 GE Healthcare Bio-Sciences 
Optical Unit UV-1 GE Healthcare Bio-Sciences 
Pump P-500 GE Healthcare Bio-Sciences 
Collector Frac-100 GE Healthcare Bio-Sciences 
Recorder Rec 112 GE Healthcare Bio-Sciences 
Program GP-250 Plus GE Healthcare Bio-Sciences 
Gel Doc™XR documentation system BioRad Laboratories GmbH 
Glassware Schott Glaswerke AG  
Plasticware Roth 
Illustra NAP-10 Column GE Healthcare Bio-Sciences 
Membrane Extruder for Laboratory:  
            LiposoFast-Basic   Avestin Inc. 
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            LiposoFast-Stabilizer  Avestin Inc. 
            Polycarbonate membrane 400 nm Avestin Inc. 
            Hamilton Syringe 1 ml Hamilton Company 
Milli Q  plus  Millipore 
MillexGP   Millipore 
Needle 22G Nr. 12 BD Microlance  
Osmomat 030  Gonotec 
pH meter 720A  ORION 
TRICARB 2800 TR Packard Tri-Carb Liquid Scintillation 
Counter 
 
PerkinElmer  
PCR-Thermocycler T Gradient Thermomixer compact Biometra 
PD-10 Desalting column  GE Healthcare Bio-Sciences 
Petri dishes for Bacterial culture (92 x 16 mm, PS) Sarstedt  
Photometer Ultrospec 2100 pro GE Healthcare Bio-Sciences 
Pipettes Eppendorf 
Plastic tubes (1.5 ml, 2 ml) Eppendorf 
Polypropylene tubes (14 ml) Greiner Bio-One GmbH 
Quantamaster 2  PTI 
Reaction tubes (0.5 ml, 1.5 ml, 15 ml and 50 ml) Sarstedt 
Reaction tubes (safe lock 1.5 ml, 2 ml) Greiner Bio-One GmbH 
SDS-PAGE system with Power Supply PowerPac™ Basic    BioRad 
Spectrophotometer Ultrospec 2100 pro  Amersham Biosciences 
Sterile filter Millex-GP Filter Unit Millipore Corporation 
Thermocycler Biometra or MJ Research 
Thermostat Plus system Eppendorf 
Unitron coulter Infors HT 
Ultrasound Sonifier 450  Branson Ultrasonics Corp. 
Vacuum concentrator 5301 Eppendorf 
Vacuum pump VACUUBRAND or KNF Neuberger 
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Table 7.4 List of chemicals used. 
 
Chemicals Company 
Acetic acid (100 %)  Merck 
Acetone Baker  
Acrylamide-Bisacrylamide 37.5:1 mixture SERVA 
Agarose Serva 
AHT (anhydrotetracycline hydrochloride) ACROS ORGANICS 
 
APS (ammonium persulphate) 
 
Serva 
 
Ampicillin, sodium salt 
 
Serva 
 
AMPSO (N-(1,1-Dimethyl-2-hydroxyethyl)-3-amino-2-
hydroxypropanesulfonic acid) 
Sigma-Aldrich 
 
Aspartic acid, L-[2,3-3H]- MP Biomedicals, Inc.  
Bacto™ Agar  Becton, Dickinson and Company 
Bio-Beads SM-2 Adsorbent™  BioRad 
BSA (bovine serum albumin)  Sigma-Aldrich 
Borat sodium salt Merck 
Bromophenol blue sodium salt AppliChem GmbH 
Calcium chloride dihydrate Merck 
dATP (2'-deoxyadenosine 5'-triphosphate) GE Healthcare Bio-Sciences 
Desthiobiotin Invitrogen 
Difco™ LB Broth, Miller (Luria-Bertani) Becton, Dickinson and Company 
di-Sodium hydrogen phosphate dihydrate Merck 
DMF (dimethylformamide) Sigma-Aldrich 
DMSO (dimethylsulfoxide) Merck 
Deoxynucleotide triphosphates (dNTPs): 100 mM dATP, 
dCTP, dGTP, dTTP 
 
Sigma-Aldrich 
 
DDM (n-Dodecyl-β-maltoside)  GLYCON Biochemicals  
DTT (dithiothreitol) Roth 
Decon 90 Decon Laboratories Limited 
EDTA (ethylendiamintetraacetic acid, anhydrous) Merck 
E. coli total Lipid Extract Avanti Polar Lipids 
Ethanol absolute Baker 
Ethidium bromide tablets USB Corporation 
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GeneRuler DNA Ladder Mix  Fermentas 
Glutamic acid, L-[3,4-3H]- Hartmann Analytic GmbH 
D-Gluconic acid, 45 to 50 wt % solution in water Sigma-Aldrich 
Glycerol (99 %, water free)  KMF Laborchemie Handels GmbH 
Glycine  Sigma-Aldrich 
Imidazole  Sigma-Aldrich 
Isoamyl alcohol Merck 
Isopropanole (2-Propanole)  Merck 
HABA (4’-Hydroxyazobenzene-2-carboxylic acid) Sigma-Aldrich 
Potassium acetate extra pure Merck 
Potassium hydrogen phosphate trihydrate Merck 
Liquid nitrogen  Linde 
Leupeptin Serva 
Lithium chloride Serva 
Lambda DNA/EcoRI+HindIII marker  Fermentas 
Low molecular weight marker (LMW) GE Healthcare 
Sulfuric acid AppliChem 
Magnesium chloride hexahydrate Merck 
Magnesium sulfate Merck 
β-Mercaptoethanol  Serva 
Methanol  Baker 
MES (morpholinoethanesulfonic acid) Sigma-Aldrich 
NMDG (N-methyl-D-glucamine) Sigma 
PCR-H2O  Braun 
PMSF (phenylmethylsulphonylfluoride) Serva 
n-Pentane Merck 
Pepstatin Serva 
Phenol:chloroform:isoamyl alcohol (25:24:1) Roth 
L-α-phosphatidylcholine Sigma-Aldrich 
PIPES (piperazine-N,N′-bis(2-ethanesulfonic acid)) Sigma-Aldrich 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) 
 
Sigma-Aldrich 
Premix ABI PRISM BigDye Terminator v1.1 
 
 
 
 
Applied Biosystems 
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QIAGEN Kits:  QIAGEN GmbH 
Plasmid DNA Purification Kit  
QIAprep Spin Miniprep Kit  
QIAquick Gel Extraction Kit  
QIAquick PCR Purification Kit   
Qiaprep 8 Miniprep Kit   
Qiaprep Spin Miniprep Kit  
Qiagen HiSpeed Plasmid Maxi Kit  
DyeEx 2.0 Spin Kit  
Roti-Blue Colloidal Coomassie staining (5x)   Roth 
Hydrochloric acid, HCl (38 %) Baker 
SAM (S-adenosyl methionine) Sigma-Aldrich 
Scintillation cocktail Rotiszint® eco plus Roth 
Silica  Sigma-Aldrich 
SDS (sodiumdodecylsulfate)  Merck 
Sodium acetate Merck 
Sodium chloride  Merck 
Sodium hydrogen phosphate Merck 
Sodium hydroxide  Merck 
Sucrose Baker 
Filter-Count LSC-cocktail PerkinElmer  
TCEP (tris(2-carboxyethyl)phosphine hydrochloride) PIERCE 
TEMED (N,N,N',N' tetramethylethylenediamine) Serva 
TRIS (tris(hydroxymethyl)aminomethane)  Merck 
Triton X-100 Sigma-Aldrich 
Valinomycin Sigma 
Water HPLC quality  Fluka 
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Table 7.5 Oligonucleotides used. Abbreviations: s = sense, as = antisense. 
 
Construct s/as Sequence primer 
pASK IBA5 ecgltP N401D  s GAACGTGGTGGGTGATGCGCTGGCGGTG 
 as CACCGCCAGCGCATCACCCACCACGTTC 
 
 
Table 7.6 Used Escherichia coli-strain 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E.coli K12: Genotype 
BL-21 (DE3) F-, ompT, hsdSβ(rβ-mβ-), dcm, gal, (DE3) tonA 
DH5α F-, φ80dlacZΔM15, Δ(lacZYA-argF)U169, deoR, recA1, endA1, 
hsdR17(rk-, mk+), phoA, supE44, λ-, thi-1, gyrA96, relA1 
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